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Abstract
The DNA Mismatch Repair Pathway Affects ATR Activation Upon Temozolomide
Treatment in MGMT-Promoter Methylated Glioblastoma Multiforme
Sachita Ganesa
2021

In many solid tumors, methylation status of the O6-methylguanine methyltransferase
(MGMT) gene promoter is a prognostic biomarker for treatment with the alkylator,
temozolomide (TMZ). In the absence of promoter methylation, the MGMT enzyme
removes O6-methylguanine (O6-meG) lesions. However, in the setting of MGMT-promoter
methylation (MGMT-), the O6-meG lesion activates the mismatch repair (MMR) pathway
which functions to remove the damage. Our group previously reported that MGMTpromoter methylation affects activation of the ataxia telangiectasia and RAD3 related
protein (ATR) in response to TMZ treatment. Whether or not MMR proteins are involved
in ATR activation in the context of MGMT-promoter methylation upon alkylation damage
remains poorly understood. To investigate the function of mismatch repair in ATR
activation, I created isogenic cell lines with knockdowns of the individual mismatch repair
proteins MSH2, MSH6, MSH3, MLH1, and PMS2 in both the MGMT- and MGMT+
backgrounds. Here, I demonstrate that MSH2, MSH6, MLH1 and PMS2 mismatch repair
proteins, specifically, are involved in the ATR-CHK1 axis, whereas MSH3 is likely not.
This study elucidates a potential mechanistic understanding of how the MMR system is
involved in ATR activation by TMZ in glioblastoma cells, which can ultimately be
exploited for therapeutic gain in a wide-variety of MMR-mutated cancers.
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1. Chapter 1: Introduction
1.1.

The role and function of O6-methylguanine methyltransferase
The enzyme O6-methylguanine methyltransferase (MGMT) removes any alkyl

damage at the O6 position of guanine. It does this by transferring the methyl group to itself
at cysteine-145 through an SN2 mechanism before degradation by the ubiquitin proteolytic
pathway1–5. MGMT removes the lesion in a stoichiometric reaction before being degraded
as a suicide enzyme4,5. In this way, MGMT does not act as a true enzyme since it is unable
to regenerate after removing just one alkyl lesion. MGMT has also been referred to as
alkylguanine alkyl transferase, or AGT, but I will refer to both the gene and enzyme as
MGMT in this dissertation.
The MGMT gene can be found on chromosome 10 at cytogenetic band q266. The
expression of the MGMT enzyme is dependent upon its promoter methylation status. The
promoter region of MGMT has been extensively studied, and there is an expansive region
of CpG islands at the promoter region meaning many cytosine and guanine (CpG) repeats.
The 5’ region of the MGMT promoter consists of 97 CpG islands spanning the minimal
promoter and enhancer region, which are important for maximal promoter activity7 (Figure
1.1). The methylation status of the enhancer element seems to be more crucial in
determining the loss of expression of MGMT, based upon data from a luciferase reporter
assay where different regions of the methylated promoter were tested across many cell
lines; thus, most assays for determining MGMT expression focus on the enhancer region8,9
(Figure 1.2).
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Figure 1.1. Map of the 5’ region of the MGMT promoter. This map shows the
minimal promoter and enhancer regions, as well as binding sites for transcription
factors, exons, and restriction enzyme sites. Image from Weller et al., 2010.

Figure 1.2. Methylation status of the CpG islands within the MGMT promoter in
various cell lines. Methylation of the enhancer region seems most critical to determine
MGMT expression. Image from Weller et al., 2010.
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There are many methods to test the expression of MGMT in cells and tissues. One
of the most common techniques is immunohistochemistry (IHC) for its simplicity and
effectiveness10,11. IHC allows the staining and differentiation between tumor cells and
surrounding healthy cells; however, this method is only semi-quantitative and does not
distinguish to which extent the MGMT promoter is methylated. IHC is being phased out as
a detection method for MGMT expression as studies have failed to correlate IHC outcomes
with more quantitative analysis methods for MGMT expression12–15. Currently, the most
common detection method for MGMT-promoter methylation analysis is methylationspecific polymerase chain reaction (MSP), where the DNA methylation pattern within CpG
islands is analyzed6,16–18. During MSP, DNA is modified and undergoes bisulfite
conversion to deaminate unmodified cytosines to uracils6. This modification leaves behind
methylated cytosine residues. The methylated sequences are then amplified by polymerase
chain reaction (PCR) using two different primer sets: one that targets methylated sites and
one that targets unmethylated sites. This will reveal the methylation status of every cytosine
within the gene specific amplification region6. MSP works well for the MGMT promoter,
as there are 97 CpG islands and thus plenty of cytosine residues to analyze (Figure 1.3).

Figure 1.3. Schematic of bisulfite conversion
for methylation specific polymerase chain
reaction. Image from Weller et al., 2010.
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Various tissues can have variable MGMT expression levels, yet tumors typically
exhibit higher levels of MGMT expression than the normal, healthy tissue surrounding the
region19. For this reason, MGMT expression has been used as both a predictive and a
prognostic biomarker20,21. A predictive biomarker can give information about the effect of
a therapeutic agent, whereas a prognostic biomarker can provide information about
patients’ overall outcome regardless of therapy. It has been shown that MGMT-promoter
methylation can increase sensitivity to treatment with alkylating agents20,22–24. Tumors with
low MGMT expression (and thus MGMT-promoter methylation) can take advantage of this
sensitivity to eliminate cancer cells. Clinical trials have shown that MGMT-promoter
methylation status can predict the prognosis of glioma patients through retrospective
analysis. Findings showed that patients with MGMT-promoter methylation likely have
favorable treatment outcomes with the alkylating agent temozolomide (TMZ) but not with
radiation therapy25,26. Additional studies showed that patients with anaplastic
oligodendroglioma predicted better overall survival and progression-free survival upon
treatment with radiation and/or alkylating agents when the tumors were MGMT-promoter
methylated27. A seminal trial from 2005 showed that glioblastoma multiforme patients who
have methylated MGMT promoter tumors responded better to treatment with the alkylating
agent TMZ than other patients24. About 50% of cancers have low MGMT expression, and
so understanding the methylation landscape of the MGMT promoter in tumors can be key
for a successful treatment regimen24.
Because low expression of MGMT has been shown to be more favorable in the
treatment of certain tumors, there have been several approaches in figuring out how to
deplete MGMT, using agents such as O6-benzylguanine (O6-bG)6,28. O6-bG is a synthetic
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derivative of guanine and acts as a substrate and suicide inhibitor for MGMT. Once O6-bG
is consumed by MGMT, MGMT is degraded and is not replenished; thus, treating cells
with O6-bG can decrease MGMT expression. Nonetheless, reports have shown that in vitro,
O6-bG is only effective for a short period of time on the scale of 6 hours29. After 18 hours,
MGMT expression was restored suggesting that it is resynthesized29. Clinically, O6-bG has
been tested in combination with TMZ for MGMT-expressing glioblastoma patients;
however, it was reported that the treatment regimen was extremely toxic without providing
much benefit to patients30. Another inhibitor, O6-(4-bromothenyl) guanine (O6-bTG) has
10-fold increased potency than O6-bG for inactivating MGMT and has been shown to be
orally bioavailable with reduced toxicity28. Clinical data has shown that O6-bTG and TMZ
combination was effective on advanced solid tumors31. Unfortunately, both O6-bG and O6bTG have high systemic toxicity due to off-target effects on healthy cells28. Because of the
off-target toxicity effects, the use of these MGMT-depleting agents is not quite ready for
clinical implementation and additional research needs to be completed to target MGMT
more thoroughly.
Overall, MGMT-promoter methylation status is critical in determining whether
MGMT is expressed or not, and MGMT expression is being explored as a biomarker for
response to treatment with alkylators such as the chemotherapeutic agent TMZ. Further
studies on safely depleting MGMT may be valuable to improve treatments for patients with
MGMT-expressing tumors.
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1.2.

Alkylating agents and temozolomide
DNA alkylating agents were first discovered in the 1940s and quickly became used

for their potential chemotherapeutic value32. Alkylating agents attach an alky group
(CnH2n+1) to DNA33. The most common alkyl adducts are found at the N7 position of
guanine and N3 position of adenine, though other alkyl lesions can be created on DNA as
well34. Before being widely used in the clinic, alkylating agents were better known for their
use in chemical warfare during World War I as sulfuric and nitrogenous mustard gas35. In
the year 1942 at Yale University, Goodman and Gilman began studying the role of nitrogen
mustards to treat tumors in mice. Later that year, these nitrogen mustards were employed
to treat humans, showing temporary reduction of tumor mass in Hodgkin’s disease
lymphosarcoma and leukemia36. Following this discovery, an abundance of new alkylating
agents was created over the next few decades for the treatment of cancers.
Alkylating agents are found commonly in the environment and within living cells,
and are found in components of air, water, biological byproducts (such as food) and
pollutants including tobacco smoke37–39. Internally, byproducts of oxidative damage can
lead to alkylation damage40,41. We are exposed to the toxicity caused by alkylation damage
daily, yet despite these dangers to our health, alkylators are used in the clinic as
chemotherapies with the ultimate purpose of killing cancer cells42. Alkylating agents seem
to be almost paradoxical: they can both induce cancer and be used to treat cancer. However,
researchers have been trying to understand the molecular landscape of cancer to target
tumors with these alkylating agents more selectively.
There are two main groups of alkylating agents, categorized by the number of
reactive sites within the drug: monofunctional alkylators, which have one reactive site, and
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bifunctional alkylators, which have two reactive sites. They can further be categorized by
their chemical reactivity (SN1 vs SN2 nucleophilic substitution), the type of alkyl group
(methyl, chloroethyl, etc.), and whether the DNA substrate is single-stranded or doublestranded. Most alkylating agents used in the clinic are SN1 agents and can be either monoor bifunctional34. Currently, there are quite a few alkylating agents available in the clinic,
but I am interested in studying one of the most used alkylators for glioblastoma, known as
temozolomide (TMZ).
TMZ is a monofunctional SN1 alkylator and was synthesized in the late 1970s by
Malcolm Stevens’ group at Aston University in Birmingham, England43. It was approved
for clinical use in the early 2000s in both Europe and the USA44,45. In the clinic, TMZ is
also referred to as Temodar or Temodal, but I will refer to the drug solely as TMZ in this
dissertation. The oral bioavailability and ability of TMZ to cross the blood-brain barrier
makes this an attractive choice of chemotherapy for central nervous system cancers, such
as glioblastoma multiforme44. TMZ is administered as a pro-drug, meaning it needs to be
metabolized in the body to activate the otherwise biologically inactive compound. At
physiological pH around 7.4, TMZ is activated and converted to the short-lived metabolite
5-(3-methyltriazen-1-yl) imidazole-4-carboxamide (MTIC)46. MTIC is hydrolyzed and
produces methyl diazonium ions which are electrophilic methylated molecules that can
cause DNA damage45,47. Because DNA is negatively charged, it acts as a nucleophile for
the positively charged methyl diazonium ions, resulting in the addition of multiple DNA
alkyl adducts causing DNA damage (Figure 1.4). TMZ is a monofunctional alkylating
agent, thus it only affects single stranded DNA instead of double stranded DNA. The most
common methylation sites of TMZ include N7-guanine and O3-adenine48. Additionally,
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about 5% of TMZ-induced damage will create alkyl lesions at O6-guanine. Even though
the O6-methylguanine (O6-meG) lesions are the least common lesion created by TMZ, they
are thought to be the lesion responsible for the overall cytotoxicity of this alkylating
agent49.
It is well-established that glioblastoma patients with a methylated MGMT promoter
have better overall survival when treated with the alkylating agent, temozolomide (TMZ)24.
As mentioned, this is because lack of MGMT allows the O6-meG to persist without
reversion to guanine causing DNA damage to the cancer cell, ultimately leading to cancer
cell apoptosis. Though there has been evidence of low MGMT expression in other tumors
such as colorectal carcinomas, small-cell lung carcinomas, lymphomas, and head and neck
carcinomas, TMZ treatment has been mostly limited to glioblastomas17,50,51. However,
resistance to TMZ and tumor recurrence is an issue, even in the MGMT-promoter
methylated setting. Glioblastomas tend to be very heterogenous and prone to new
mutations, making resistance inevitable52,53. Unfortunately, there are not many other
predictive markers for response to TMZ besides MGMT-promoter methylation status.
In summary, TMZ is a commonly used as an alkylator to treat glioblastoma and
other cancers. TMZ can take advantage of MGMT status in providing better outcomes for
those patients with MGMT-promoter methylated tumors. However, TMZ resistance can
arise and is complicated by new mutations that arise and the lack of knowledge surrounding
how those mutations affect response to TMZ. Thus, studying the DNA repair pathways
that TMZ recruits can allow us to understand how to mitigate TMZ resistance.
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Figure 1.4. Temozolomide metabolism. TMZ forms into the short-lived MTIC
before becoming methyl diazonium ions. These positively charged atoms can
methylate DNA at various positions. Image from Singh et al., 2021.
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1.3.

DNA damage response pathways
Our cells are prone to damage that can harm the DNA in our cells, and thus

preserving our genomic integrity is required for cellular function. Damage to our genome
can arise in multiple ways, including both externally and internally, but the most serious
forms of genomic damage affect DNA directly and can cause cancer54. For example,
extraneous ultraviolet (UV) damage caused from the sun and environmental factors can
induce cellular stress and genomic instability which would need to recruit DNA damage
response (DDR) pathways to repair the damage55. Intracellularly, DNA damage can occur
due to DNA replication, reactive oxygen species generated by respiration, and the
spontaneous hydrolysis of DNA nucleotides. Given the sheer amount of damage our DNA
encounters, which is approximately 104 to 105 lesions daily, there are many cellular
mechanisms in place to repair the damaged lesions and maintain genomic integrity54.
In nature, the simplest forms of cellular defense against DNA damage evolved to
selectively reverse one type of damage. For example, some types of UV-induced damage
can be reversed by special enzymes known as photolyases56. Another great example of an
enzyme with the ability to selectively reverse one type of damage is MGMT, as discussed
above. As an enzyme, MGMT’s only function is to remove any O6-meG lesions that may
arise due to alkylation5. However, enzymes with solely one function to remove one specific
type of lesions are not common, and there are more complex mechanisms and pathways
required to remove more diverse types of DNA damage. Despite a vast amount of research
published on the DDR pathways, there are still controversies regarding which pathways
are activated by certain types of damage or lesions due to a fair amount of overlap between
these mechanisms.
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DDR pathways can be vaguely categorized into single-strand break repair and
double-strand break repair. Within these categories, there are a plethora of other smaller
repair pathways. Some of the common pathways in single-strand break repair are base
excision repair (BER) or nucleotide excision repair (NER). During BER, bases that have
small chemical alterations (such as those due to alkylation) that do not disturb the structure
of the DNA double-helix are repaired57,58. First, DNA glycosylases that are specific to the
lesion will identify and eliminate the damaged base from the sugar-phosphate backbone of
the DNA. The removal of the base will leave an abasic (AP) site exposed for APendonuclease to cleave before DNA polymerase β will replace the base, and XRCC1/ligase
III will seal any breaks in the DNA. A special type of BER will involve the nuclear protein,
poly(ADP-ribose) polymerase (PARP) which will parylate single-strand breaks recruiting
XRCCI/ligase III again59–61. NER is more complex than BER as it requires excision and
replacement of an entire nucleotide that can destabilize the DNA helix, instead of simply
removing a base62,63. There are many proteins involved in NER depending on the type of
nucleotide lesion, but notably replication protein A (RPA) will prevent single-strand DNA
from reannealing, and polymerase β and ligase III can both be recruited to replace and
ligate the lesion64,65. Double-strand break repair is more complex than BER or NER and is
usually split into the 2 distinct pathways of homologous recombination and
nonhomologous end-joining, which involve a plethora of additional proteins66–68. As
mentioned prior, there is plenty of overlap between these pathways, which is why it is
important to acknowledge them. The one pathway I am particularly interested in studying
is the DNA mismatch repair pathway.
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1.3.1. Mismatch repair pathway
The mismatch repair (MMR) pathway can be categorized as one of the mechanisms
of single-strand break repair and is a highly conserved pathway that plays a critical role in
maintaining and preserving our genome69. MMR is typically recruited upon mismatches
between bases or upon insertions and deletion mismatches that occur during replication69.
This system is particularly important in preventing mutations from becoming permanent
and passed down through cells that are dividing, making MMR imperative in both the
short-term and long-term.
Escherichia coli (E. coli), yeast, and human MMR all have very similar functions,
further exemplifying its importance as it is conserved across many organisms70–72. In
eukaryotes, MMR consists of two families of proteins which are heterodimers: MutS and
MutL, which are homologs from E. coli. In the first step of the MMR pathway, the
mismatch is recognized by either MutSα or MutSβ. MutSα is a heterodimer composed of
the proteins MSH2 and MSH6, and MutSβ is composed of MSH2 and MSH371–73. Whereas
MutSα is responsible for recognizing base-base mispairs and small indels on the order of
1 to 2 nucleotides, MutSβ is responsible for recognizing indels of 1-15 bases69,74. The
binding of MMR proteins to the mismatch then allows the conversion of ADP to ATP,
converting these heterodimers into sliding clamps that can glide along the DNA to look for
additional mismatches74,75. The sliding of these heterodimers will then allow for the
interaction with the MutLα heterodimer, composed of proteins MLH1 and PMS276. Upon
MLH1 recruitment, excision occurs where the MMR proteins must excise the error from
the newly synthesized strand that has the error, as opposed to the template strand. In a 5’
reaction, MutSα activates the exonuclease EXO177. MutLα has been found not necessary
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for all 5’ repair, though when present can modulate excision74,76. In the event of a 3’
mismatch which is less studied and understood, MutLα activity has been shown to be
essential76,78. After excising the lesion, a DNA polymerase will replace the lesion, and
DNA ligase I will fill the gap of the DNA duplex74 (Figure 1.5).

Figure 1.5. Schematic of eukaryotic mismatch
repair. Upon recognition of the mismatch by MutSα
or MutSβ, MutLα is recruited along with EXO1 to
excise the mismatch. Then DNA polymerase and
DNA ligase resynthesize and ligate the DNA,
respectively.
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Upon alkylation damage from TMZ, O6-meG lesions will mispair with thymine
instead of cytosine79. In the absence of the MGMT enzyme to remove the O6-meG lesion,
MMR will be recruited to excise the thymine mismatch. However, in this case, the MMR
proteins will fail to replace thymine with cytosine and will continually add another
thymine. This iterative replacement of thymine with itself will result in a phenomenon
known as futile cycling, ultimately leading to additional DNA breaks and cell death79. The
model of futile cycling is heavily debated as many believe that it is the primary method of
TMZ toxicity while others consider that there are other mechanisms at play for TMZinduced cell death80 (Figure 1.6).
Understanding the role of MMR is important for its clinical significance. Mutations
in MMR can affect genomic stability, resulting in a phenotype known as microsatellite
instability (MSI)81. Microsatellites are repeated sequences of DNA, though the most
common is with the cytosine and adenine nucleotides82. When MMR mutations are unable
to repair a replication error, an MSI region is created83. Adding MSI regions that should
not originally exist can result in frame-shift mutations, leading to a slew of issues within
the cell and creating a higher predisposition to cancer83. MMR mutations and MSI are
associated with cancers ranging from colon cancer to gastric, ovarian, and brain cancers
including glioblastoma84. Further, germline MMR mutations can lead to Lynch syndrome,
which increases the risk of being diagnosed with any of the cancers previously
mentioned85,86. There have also been documented cases of glioblastoma patients
developing resistance to TMZ and acquiring new mutations within the MMR pathway87–
89

.

14

To conclude, studying the intricacies of the MMR pathway is fundamental in
understanding how to maintain genomic integrity, and how to take advantage of the system
in the setting of cancer. MMR is relevant pertaining to the clinic; being able to dissect this
complex pathway as it relates to TMZ-induced alkylation in the context of MGMTpromoter methylation may enlighten physicians and scientists to develop new
chemotherapies for patients.

Figure 1.6. Temozolomide-induced mismatch repair futile cycling model. MMR
proteins will continually replace thymine with itself, and iterative cycles of this will
lead to futile cycling, DNA breaks, and cell death through apoptosis.
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1.4.

Ataxia telangiectasia and RAD3 related protein in DNA repair
Ataxia telangiectasia and RAD3 related protein (ATR) is a crucial protein in

regulating genomic stability, much like the other DDR pathways and proteins mentioned
previously90. ATR, ataxia telangiectasia mutated (ATM) and DNA-dependent protein
kinase (DNA-PK) are members of the PI3K-like kinase (PIKK) family. All three of these
kinases play a role in DNA damage signaling, though ATM and DNA-PK are activated by
double-stranded breaks and ATR is mostly activated by single-strand breaks91,92. Though
these kinases have all been well-studied for their distinct roles, there is still quite some
overlap between these pathways upon certain types of DNA damage, which remains
understudied and controversial. Specifically, it is still unknown how ATR is activated by
DNA damage and replication stress93.
ATR is an essential protein unlike the other kinases, as its absence has been shown
to lead to embryonic lethality. The activation of the ATR pathway begins with a singlestrand break. Replication protein A (RPA) will coat the single-stranded DNA to prevent it
from reannealing onto itself. ATR-interacting protein (ATRIP) then directly binds to RPA,
allowing the ATR-ATRIP complex to recognize the DNA damage site or stressed
replication, and recruits RAD1794. The pathway continues as the 9-1-1 complex (RAD9,
RAD1, and HUS1), and Topoisomerase Binding Protein I (TopBP1) are also recruited to
the site of damage. This mechanism is thought to be one of the pathways by which ATR is
activated95–97 (Figure 1.7). Upon activation of ATR, it can phosphorylate its downstream
substrate, CHK194. The phosphorylation of CHK1 at serine 317 and serine 345 are often
used as well-characterized markers for ATR activation, as ATR is the sole kinase to
phosphorylate these serine residues98. Including the phosphorylation of CHK1, further
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downstream of ATR signaling continues to be complex. CHK1 phosphorylation has been
known to activate the CHK1 protein, which will then phosphorylate CDC25, a regulator of
cell cycle phases99,100. ATR activation has also been shown to induce G2/M arrest101.

Figure 1.7. Upstream activation pathway of
ATR. RPA is recruited to single-strand DNA
(ssDNA) before the recruitment of ATRIP and
RAD17. Then, the 9-1-1 complex and TopBP1
are recruited, all assembling to activate ATR.
Image from Shiotani and Zou, 2009.
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ATR appears to serve a greater purpose in tumor cells than in normal cells99. ATR
is involved in an entire signaling cascade with many moving parts, and tumor cells tend to
be dysregulated in various parts of this pathway and have higher levels of replication stress.
Studies have shown that inhibiting the ATR pathway can be selectively toxic in cancer
cells, leading to the development of ATR inhibitors. The first ATR inhibitor identified was
caffeine, as it disrupts cell-cycle arrest caused by DNA damage and sensitizes cells to DNA
damage102. Caffeine is not selective for ATR alone and also targets ATM, requiring high
toxic doses for clinical effect in cancer cells99,102. For this reason, there has been the
development of other ATR inhibitors. In 2011, the first potent and selective ATR inhibitor
was created by Vertex Pharmaceuticals, VE-821, and a few years later its improved analog
VE-822 (also known as VX-970 to be used later in Chapter 6 was created103,104. VX-970
was the first ATR inhibitor to enter clinical trials, making its use in the in vivo studies of
this dissertation relevant. AstraZeneca and Bayer Pharmaceuticals have also created
structurally unique, highly selective, and potent ATR inhibitors, AZ-20 and BAY1895344, respectively, with sub-micromolar concentrations required for cancer cell
kill105,106 (Figure 1.8).

Figure 1.8. Structure of ATR inhibitors AZ-20, BAY-1895344, and VX-970.
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CHK1 is a downstream substrate of ATR, and thus there have also been CHK1
inhibitors in development. It is possible that these inhibitors do not differ significantly from
ATR inhibitors due to their close relation, though CHK1 inhibitors are in clinical trials as
well. It appears ATR inhibition may have a wider clinical range than CHK1 inhibitors,
making ATR inhibitors a better choice for study107,108.
Recently, work published from our laboratory showed that ATR is activated in
MGMT-promoter methylated cancers upon treatment with TMZ. Western blotting showed
earlier ATR activation through pCHK1 levels in MGMT-promoter methylated cells
(MGMT-) vs. cells with MGMT (MGMT+)109. Additionally, TMZ sensitizes MGMT- cells
to ATR inhibitors as seen from synergy plots. This data led us to believe that perhaps MMR
futile cycling is not the only method of TMZ toxicity, but that TMZ can also lead to
replication stress, ATR signaling, and subsequently cell death (Figure 1.9).
A

B

C

Figure 1.9. ATR signaling is specific to MGMT- cells and not MGMT+ cells. (A)
Western blot with TMZ-treated MGMT- and MGMT+ cells over 48 hours shows earlier
activation of ATR in MGMT- cells. (B) There is exquisite synergy with TMZ and ATR
inhibitor in only MGMT- cells. (C) TMZ may activate ATR signaling, not only MMR.
Images from Jackson et al., 2019.
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1.5.

Significance and Innovation
Given that canonically TMZ-induced damage leads to MMR, and that a publication

from our lab previously showed that TMZ causes ATR activation occurs in MGMT- cells,
the next logical step is to understand if and how MMR affects ATR signaling109.
Previously, it has been published that MMR plays a role in ATR signaling but the specific
proteins involved have not been teased out110. In this dissertation, I sought to investigate
the role of the DNA mismatch repair system as it relates to ATR activation upon TMZ
treatment in glioblastoma multiforme. This study is novel and data pertaining to this
research question has not been published to the best of my knowledge.
To ensure that I thoroughly study each MMR protein for its individual and unique
roles, I started by creating shRNA knockdown cell lines of all the MMR proteins in both
the MGMT- and MGMT+ context. These isogenic cell line models are unique in allowing
me to isolate one specific protein in the context of MGMT-promoter methylation. Using
these cell lines, I then investigated the role of TMZ-induced ATR activation upon loss of
the MMR protein in assays ranging from in vitro western blots to in vivo mouse studies. If
ATR signaling was affected in the MMR knockdown cell lines compared to the parental
MMR-proficient cell lines, then I would be able to conclude that that individual MMR
protein is associated with ATR signaling.
Understanding how MMR is involved in ATR signaling upon TMZ-induced
damage has significant clinical implications. Many cancers have MMR deficiencies, so
studying the molecular landscape of these cancers can allow for more targeted therapies
with combinations of TMZ and ATR inhibitor. Overall, the data presented here can
ultimately be helpful to target and treat a wide-variety of MMR-mutated cancers.
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2. Chapter 2: Materials and Methods
2.1.

Cell culture

Human glioblastoma LN229 MGMT- and MGMT+ cell lines were obtained from Bernd
Kaina (Johannes Gutenberg University Mainz, Mainz, Germany). U251 cells were
purchased from Horizon. All cells were confirmed negative of Mycoplasma using qPCR.
Cells were cultured in DMEM with 10% FBS.

2.2.

Mismatch repair knockdown cell line creation

The pGIPZ™ shRNA lentiviral vectors for mismatch repair proteins MSH2, MSH3,
MSH6, MLH1 and PSM2, were purchased as glycerol stocks from Horizon Dharmacon™
(Table 2). Nontargeting GIPZ lentiviral shRNA particles were purchased from Horizon
Dharmacon™. From the glycerol stock, the shRNA plasmids were prepared and confirmed
by restriction digest with SacII. To generate lentiviral particles, HEK293T cells were
transfected with the shRNA lentiviral plasmid of interest, a packaging plasmid (psPAX2,
12260 from Addgene), and an envelope plasmid (pCMV-VSV-G, 8454 from Addgene)
using Lipofectamine™ 3000 Transfection Reagent (Invitrogen, L3000001). Viral particles
were harvested from the cell media after 48h. To create the cell lines, LN229 MGMT- and
MGMT+ cells were infected with a high titer of shRNA lentivirus of interest and 8 µg/mL
of polybrene. 48 hours later, cells were selected with 1 µg/mL of puromycin for 3-4 days
before use. Cells were harvested as a polyclonal population and confirmed for the protein
knockdown with western blotting before proceeding with limiting dilution to create
monoclonal cell populations which were then confirmed by western blotting.
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Table 2. shRNA glycerol stock information.
Protein shRNA information

shRNA sequencing primer

MSH2

Entrezgene 4436, RHS4430-200305416

5' - GCATTAAAGCAGCGTATC - 3'

MSH3

Entrezgene 4437, RHS4430-200158125

5' - GCATTAAAGCAGCGTATC - 3'

MSH6

Entrezgene 2956, RHS4430-200281418

5' - GCATTAAAGCAGCGTATC - 3'

MLH1

Entrezgene 4292, RHS4430-200268977

5' - GCATTAAAGCAGCGTATC - 3'

PMS2

Entrezgene 5395, RHS4430-200253216

5' - GCATTAAAGCAGCGTATC - 3'

2.3.

Drug compounds

All drug compounds were purchased from SelleckChem. Compounds were resuspended as
a stock concentration in DMSO, aliquoted, and stored at -20C: temozolomide (S1237), AZ20 (S7050), BAY-1895344 (S9864), VX-970, AZD7648 (S8843), AZD0156 (S8375), and
AZD7762 (S1532).

2.4.

Western blot and immunoprecipitation
Cells were treated with drug where indicated, trypsinized and pelleted for use

immediately or placed in storage at -80C. Cells were lysed on ice with 1X RIPA buffer
(Cell Signaling Technology, 9806S) and 1X Halt™ Protease and Phosphatase Inhibitor
Single-Use Cocktail (ThermoFisher Scientific, 78442). The lysed cell pellets remained on
ice for 30 minutes while briefly vortexing every 5 minutes for 10 seconds. Lysed cell pellets
were centrifuged for 10m at 4C. The remaining lysates were quantified using the Bradford
protein assay.
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For immunoprecipitation (IP), cells were lysed in lysis buffer (50 mM HEPES, 250
mM NaCl, 1% NP-40, 5 mM EDTA, and 1X Halt cocktail). The lysed cell pellets were
sonicated 5 seconds on/10 seconds off for 15 seconds at 100% and then centrifuged for
25m at 4C. The lysates were quantified using the Bradford protein assay. Equal
concentrations of protein lysates were bound to 0.5 mg of magnetic Protein G Dynabeads
(Invitrogen, 10003D) along with 1.5 µg of CHK1 antibody and incubated on a rotator
overnight at 4C. The following day, beads were collected and washed once with wash
buffer (50 mM HEPES, 250 mM NaCl, 0.1% NP-40, 5 mM EDTA, and 1X Halt cocktail),
once with high-salt wash buffer (50 mM Tris pH 7.5, 1 M NaCl, 1% Triton X-100, 1 mM
DTT, 10% glycerol, and 1X Halt cocktail), and once more with wash buffer. Protein was
eluted from the beads by resuspending in 2X Laemmli in wash buffer before boiling for
5m at 70C.
For both western blot and IP, protein was separated using NuPAGE™ 4 to 12%,
Bis-Tris gels and transferred to a PVDF (polyvinylidene fluoride) membrane at 90 volts
for 90 minutes. After 1 hour of blocking in 5% BSA or 5% non-fat dry milk in 1X TBS-T,
membranes were incubated at 4C overnight in primary antibody.
The following primary antibodies were used as indicated in Table 3. The following
day, membranes were washed in 1X TBS-T and incubated with peroxidase-conjugated
secondary antibodies at room temperature at 1:5000 in 1X TBS-T for 1-2 hours before
visualizing the signal with the Clarity ECL kit (BioRad, 1705061).
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Table 3. Antibodies and dilutions for western blot and immunoprecipitation.
Antibody

Company

Catalog

Blocking

Dilution

pCHK1 S317

Cell Signaling Technologies

12302

5% BSA

1:666

pCHK1 S345

Cell Signaling Technologies

2348

5% BSA

1:666

pCHK1 S296

Cell Signaling Technologies

2349

5% BSA

1:666

CHK1

Cell Signaling Technologies

2360

5% milk

1:1000

CHK1

SantaCruz

SC-8408

5% milk

1:500

MGMT

Cell Signaling Technologies

2379

5% BSA

1:1000

MSH2

Cell Signaling Technologies

2850

5% milk

1:1000

MLH1

Cell Signaling Technologies

4256

5% BSA

1:1000

MSH3

BD Biosciences

611390

5% BSA

1:666

MSH6

BD Biosciences

610918

5% BSA

1:1000

PMS2

ProteinTech

66075-1-Ig

5% milk

1:1000

GAPDH

ProteinTech

HRP-60004

1X TBS-T

1:10000

2.5.

Short-term cell viability and drug synergy assays

Cells were seeded at 1,000 cells per well in a 96-well plate. The following day, cells were
treated with various concentrations of drugs as indicated. After drug treatment of 3 days,
or 6 days with temozolomide, cells were washed once in 1X PBS, fixed in 4%
paraformaldehyde, and stained with Hoescht at 1 µg/mL. Plates were imaged on Cytation
3 (BioTek) and counted using cell profiler (http://cellprofiler.org). For synergy assays,
synergy was calculated using Combenefit 111.
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2.6.

Clonogenic survival assay

Cells were pretreated with temozolomide in culture for 72h. Cells were then seeded in fresh
media without drug in 6-well plates in triplicate, at a 3-fold dilution ranging from 9,000 to
37 cells per well. After seeding, cells were treated with ATRi and placed plates in the 37C
incubator. After 14 days, plates were removed, washed with 1X PBS, and stained with
crystal violet for 1 hour. Colonies were counted by hand and counts were normalized to
the plating efficiency of corresponding drug treatment condition.

2.7.

Immunofluorescence

Cells were seeded in clear bottom, black 96-well plates at 10,000 cells/well (Grenier,
655866). At the stated times, cells were treated with drug. The pRPA32 S33 protocol was
described previously 93. Cells were incubated with primary antibodies at 4C overnight, at
1:1000 dilution of pRPA32 S33 (Bethyl, A300-246A) and 1:500 dilution of antiphospho-histone H2A.X Ser139 clone JBW301 (Millipore Sigma, 05-636). Secondary
antibodies dilutions were 1:500, and Hoescht 33342 at 1 µg/mL. Cells were imaged on a
Keyence BZ-X800 and foci were analyzed using the Focinator 112.

2.8.

Flow Cytometry

For propidium iodide (PI) staining, cells were seeded in 6-well dishes 24-48h before drug
treatment. After drug treatment, cells were harvested by trypsinization before being fixed
with 70% ethanol. Cells were then stained with RNAse/PI buffer (BD Biosciences,
550825) 30 minutes before analysis on a CytoFLEX Flow Cytometer. All experiments
were performed in triplicate and analyzed using FlowJo software.
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2.9.

In vivo studies with temozolomide and ATRi

Female athymic nu/nu mice (Hsd: Athymic Nude-Foxn1nu, Envigo) were used for in vivo
studies. LN229 MGMT- or LN229 MGMT- shMSH6 cells were injected subcutaneously
into the right and left flank at a concentration of approximately 5 million cells per 100 µL
of Matrigel (Corning, 354234). Prior to treatment, mice were randomized into four groups
of 8-9 animals, where each group was similar in average starting tumor volume. Mice were
treated and tumors were measured as described previously109. All studies were approved
though the Institutional Animal Care and Use Committee at Yale School of Medicine (New
Haven, CT).

2.10. Statistical analysis
Data are presented as mean ± SD for flank studies or SEM. Student’s t test or 2-way
ANOVA (xenograft studies) were used to make comparisons. Statistical analyses were
carried out using GraphPad PRISM. Asterisks indicate levels of significance and p-value
(*≤0.05, **≤0.01, ***≤0.001, ****≤0.0001).
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3. Chapter 3: LN229 MGMT- cells show differential ATR
activation than MGMT+
3.1.

Introduction
Using relevant cell line models is key in any rigorous scientific experiment,

especially when trying to gain mechanistic insight. Because my work focuses on
understanding the mechanisms underlying temozolomide treatment in glioblastoma
multiforme, I wanted to use an established glioblastoma multiforme cell line. Thus, I chose
to use adherent human LN229 glioblastoma cells, which were established from a 60-yearold female Caucasian patient with right frontal parieto-occipital glioblastoma in 1979.
These cells have been used in a wide range of studies previously and can form tumors in
nude mice which will be useful as discussed in Chapter 6. Additional characteristics of
these cells are that they have p53 with a proline to leucine mutation at residue 98, are wildtype for PTEN, and have a deletion of p16113.
The LN229 cells are MGMT-promoter methylated as the wild-type, parental cell
line meaning that they do not express the MGMT enzyme (MGMT-). Though I am
interested in studying the mismatch repair system in the MGMT- setting, it is important to
also perform experiments in a cell line that expresses MGMT (MGMT+) as a control. My
goal is to have an isogenic pair of cell lines to identify how MGMT-status affects DNA
repair in the context of MMR and TMZ-treatment. To this end, the lab previously obtained
an LN229 MGMT+ cell line from Johannes Gutenberg University Mainz, Mainz,
Germany. The LN229 MGMT- cells were transfected with human MGMT cDNA cloned
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into a mammalian expression vector (pSV2MGMT), and were selected with G418,
allowing the expression of the MGMT enzyme114.
In 2005, a seminal trial published results that glioblastoma patients with MGMTpromoter methylated tumors responded more favorably to treatment with the alkylating
agent TMZ than patients with an unmethylated MGMT promoter24,49. This finding sparked
many investigations into understanding how TMZ-induced damage is repaired by the
MGMT enzyme, and how damage accrues in the MGMT- setting22,26,27,48. Most studies
revealed that in the MGMT- context, TMZ-induced O6-meG lesions remain unrepaired
causing more deleterious damage. This accumulated damage ultimately leads to cell death
through many debated hypotheses, which is why it is believed that the MGMT- tumor cells
respond better to TMZ treatment. One of these hypotheses proposes that the unrepaired O6meG lesions will recruit the proteins in the MMR pathway115. These MMR proteins will
attempt to repair the mismatch between O6-meG and thymine but will iteratively replace
thymine with itself, ultimately leading to cell death after numerous cycles of futile
cycling80. This is only one proposed mechanism of TMZ-induced toxicity in the MGMTsetting, but not the only one.
Previously, our group published that upon TMZ treatment, MGMT- cells activate
the ATR/CHK1 axis earlier than MGMT+ cells as seen through the phosphorylation of
CHK1109. Additionally, we reported that TMZ can sensitize MGMT- cells to treatment with
ATR inhibitors. This finding opened a new hypothesis that perhaps futile cycling is not the
only mechanism of TMZ toxicity. Thus, as a first step, I wanted to verify the MGMT-status
of my cell lines and confirm that they are responding to TMZ treatment as expected. Then,
it was important for me to recapitulate the findings from our publication that ATR is

28

activated earlier in MGMT- cells upon TMZ treatment than MGMT+ cells through western
blotting and synergy assays as presented in this chapter. These first experiments are crucial
in creating a strong foundation for the rest of the data presented in this dissertation.

3.2.

Results
3.1.1. MGMT- cells are more sensitive to TMZ than MGMT+ cells
To verify the MGMT status of my cells, I first completed a western blot on whole cell
lysates probing for MGMT. I observed that the promoter methylated MGMT cells do
not express MGMT, whereas the cells with the overexpression construct of MGMT
do express the protein in high quantities (Figure 3.1). The cell lines were acquired as
mentioned prior.

Figure 3.1. Western blot of LN229 cell line
models showing MGMT status.
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It is known that MGMT- patients respond better to TMZ treatment than MGMT+
patients24. Thus, the same principle should apply in MGMT-/MGMT+ cell lines, and
has been shown previously by work published from our laboratory. I performed a
short-term cell viability assay assessing whether I could recapitulate the known
phenotype that MGMT- cells are more sensitive to TMZ than MGMT+ cells. Upon
increasing doses of TMZ over a 6-day treatment, the MGMT- cells are sensitive and
do not survive at high concentrations of the drug, whereas the MGMT+ cells are
resistant to TMZ treatment even at the highest concentrations (Figure 3.2).

Figure 3.2. Short-term cell viability assay with temozolomide in MGMT- and
MGMT+ cells. After treatment with TMZ at high concentrations, the MGMT+ cells (top,
blue line) remain resistant compared to MGMT- cells (bottom, red line).
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Additionally, the clonogenic survival assay (CSA) has been the gold-standard of
determining drug sensitivity116. The CSA measures drug sensitivity in cells after either
constant drug treatment or the prolonged effect of drug pre-treatment, for 10-16 days
before fixing, staining, and quantifying cell colonies. Thus, I performed a CSA in these
cell lines with TMZ and found striking results that MGMT- cells are more sensitive to
TMZ whereas the MGMT+ cells remain resistant to treatment, consistent with what
we have reported previously (Figure 3.3).

Figure 3.3. Clonogenic survival assay with temozolomide in MGMT- and MGMT+
cells. After pre-treating cells with indicated concentrations of TMZ for 72 hours, I seeded
cells in triplicate in 6-well plates and allowed cells to incubate for 14 days without
additional drug before fixing and staining. The MGMT+ cells (top, blue line) remain
resistant to TMZ compared to MGMT+ cells (bottom, red line) after prolonged exposure to
TMZ.
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3.1.2. TMZ and ATR inhibitor synergize in MGMT- cells
Published work from our laboratory previously detailed that TMZ can further sensitize
MGMT- cells to ATR inhibitors109. The information gained from that novel study
could potentially be used as a new avenue to selectively treat MGMT- patients with
the combination of TMZ and ATR inhibitors. As has already been shown in Jackson,
et al. 2019, the MGMT- cells exhibit synergy upon treatment with TMZ and ATR
inhibitors, whereas the MGMT+ do not. This suggests that MGMT status plays a role
in the synergistic interaction of this drug combination. I repeated this experiment to
once again confirm the MGMT status of my cells, expecting synergy in the MGMTcells upon TMZ and ATR inhibitor treatment, which is what I observed with 2
structurally unique ATR inhibitors, BAY-1893455 and AZ-20 (Figure 3.4).
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A

B

Figure 3.4. Synergy plots of MGMT- and MGMT+ cells with
temozolomide and ATR inhibitors. (A) MGMT- cells treated with TMZ and
the combination of ATR inhibitor BAY-1895344, or (B) AZ-20. Synergy is
defined as the combination of 2 drugs causing increased cell killing more than
each drug individually. The deep blue color on the two left-sided graphs
indicates synergy and increased cell kill. The MGMT+ cells do not show
synergy or increased cell kill, as indicated by the light green area on graphs.
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Because the entirety of this thesis is based on understanding the underlying
mechanisms of why MGMT- cells activate ATR earlier than MGMT+ cells, it was
imperative to be able to recapitulate the phenotype observed through western blotting.
Previously published data in the laboratory showed an increase in phosphorylated
CHK1 levels, a direct downstream substrate of ATR109 (Figure 1.9). However, when
first attempting to repeat these western blots, I was met with great difficulty despite
attempting the western blot numerous times and changing various conditions (Figure
3.5). This led me to extensively optimize a protocol for a CHK1 immunoprecipitation
(IP), allowing me to pull-down with CHK1 and probe for pCHK1. The development
of this novel protocol would also ensure a greater signal and decreased noise, to
enhance the signal to noise ratio compared to a whole cell lysate western blot.
After many attempts with multiple protocols and minute changes, I optimized the
CHK1 immunoprecipitation as detailed in Section 2.4 (p. 22). After seeding cells in
15 cm dishes and waiting to harvest until confluent, I was left with sizable cell pellets
for lysis. The initial lysis volume was kept low at 200 µL per pellet to increase the
concentration of the lysate. The protein lysates were bound at equal concentrations,
no less than 1 mg of protein per sample, to increase the signal of pCHK1 expression.
Before the overnight binding step, I increased the volume of lysates, beads, and
antibody to 1 mL in wash buffer to allow greater surface area for the binding to occur.
After many attempts, a successful IP showed increased and earlier ATR activation
through pCHK1 levels in MGMT- cells after various concentrations of TMZ treatment
(Figure 3.6).
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A

B

Figure 3.5. Attempts at pCHK1 western blot. Failed attempts at probing for pCHK1
after (A) changing blocking conditions from 5% milk to 5% BSA, to using a MES gel
instead of the typical MOPS gel, and (B) setting up the experiment multiple times
without success. This led me to develop a very optimized CHK1 immunoprecipitation
protocol.
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A

B

Figure 3.6. Successful CHK1 immunoprecipitation showing earlier ATR
activation in MGMT- cells with temozolomide treatment. (A) IP with various
concentrations of TMZ showing increased pCHK1 levels at 4h in MGMT- compared
to MGMT+ cells. (B) Whole cell lysate showing MGMT status.
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3.3.

Discussion
Validating the cell lines and recapitulating the phenotype seen previously is

valuable before proceeding further with experiments, as it also confirms the legitimacy of
newer work. In this chapter, I authenticated the LN229 MGMT- and MGMT+ cells through
many techniques including short-term cell viability assays and the clonogenic survival
assay. From this, I confirmed that the MGMT- cells are sensitive to TMZ compared to the
MGMT+ cells. Additionally, I recapitulated the phenotype that the MGMT- cells have
earlier ATR activation seen through pCHK1 levels upon TMZ treatment compared to the
MGMT+ cells in an immunoprecipitation.
For most of my research, I focus on using LN229 glioblastoma cells although there
are other options for glioblastoma cell line models. These cell lines include U87
glioblastoma cells, T98G glioblastoma cells, and U251 glioblastoma cells (though these
cells are later used briefly in Chapter 5).
U87 cells are a hypodiploid cell line, with most cells containing about 44
chromosomes as opposed to the 46 chromosomes found in healthy human cells. This cell
line forms tumors in nude mice, making it a suitable option for our in vivo studies.
However, the origin of this cell line has not been fully confirmed as glioblastoma and has
been deemed to be “likely” from glioblastoma of the central nervous system origin117.
Though this cell line has been used extensively in the literature presumed as glioblastoma
cells, I preferred to use a glioblastoma cell line that had had its origin confirmed prior.
T98G cells contain a hyperpentaploid chromosome count, meaning most cells have
between 128 and 132 chromosomes. Additionally, these cells exhibit stationary G1 arrest
in vitro making them a poor candidate for cell cycle studies, which will be a technique
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employed later in Chapter 6118. These cells are also not tumorigenic in nude mice, proving
difficult for potential in vivo studies. T98G cells express high levels of the MGMT enzyme
at baseline, which means that MGMT must be silenced to create an isogenic cell line pair
as a model system119. Though O6-benzylguanine has been used to silence MGMT in cells,
it is a transient silencing method and would not be applicable for long-term experiments or
in the clinic30. It would be possible to complete a CRISPR knockout of the MGMT enzyme,
but this poses more challenges with potential off-target effects from the guide RNA. Thus,
using the isogenic LN229 pair with the MGMT+ overexpression cell line would prove to
be more suitable for the experiments proposed going forward.
Finally, the U251 cell line is thought to be derived from a glioblastoma. However,
controversy arose when there were similarities between the U251 cell line and the U373
cell line, both originating from the same laboratory in Uppsala, Sweden120. Because of the
confusion in identity between cell these lines, I chose not to use the U251 cell line as the
first choice for a glioblastoma cell line model. Because of these reasons listed, the LN229
cells were the best option to proceed for further investigation and mechanistic studies.
One thing to consider is that the original paper from our laboratory shows ATR
activation in MGMT- cells; however, ATR activation is still present in the MGMT+ cells
at later time points as seen from the western blot (Figure 1.9). This suggests that the ATR
pathway could be activated in the MGMT+ cells, given increasing pCHK1 levels after 48
hours, or that the cells could be suffering from other toxicity and damage leading to ATR
activation121. However, this is broad speculation and further studies to probe the kinetics
of ATR activation depending on MGMT-status are required. The increase in pCHK1 levels
were also seen in the immunoprecipitations that I optimized. Interestingly, it seems that
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different concentrations of TMZ affect ATR signaling through pCHK1 levels over time.
For example, it appears that the higher concentrations of TMZ at 50 µM and 100 µM induce
greater ATR activation earlier in the MGMT- cells over time, and the MGMT+ cells never
reach the same pCHK1 levels. This data prompts additional experiments to see how TMZ
concentration can affect ATR activation in MGMT- vs. MGMT+ cells and would shed
light on optimal dosing concentrations for enhanced therapeutic gain in glioblastoma
patients.
Overall, this chapter covered the validation of the LN229 MGMT- and MGMT+
cell lines and provided rationale for using these cell lines over other models. In future parts
of this dissertation, I will continue with the LN229 cell line model which will be key in
creating the MMR knockdown cell lines as discussed in Chapter 4.
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4. Chapter 4: Creation of shRNA mismatch repair knockdown
cell lines
4.1.

Introduction
As mentioned previously, using the correct cell line model is fundamental when

looking to characterize the role of a specific protein. Because I am interested in
understanding the role of individual MMR proteins in ATR activation, I needed to create
controlled isogenic cell lines with knockdowns for the individual MMR proteins in both
the MGMT- and MGMT+ setting. This will allow me to study how the specific knockeddown MMR protein may play a role in ATR activation upon TMZ-induced damage, and
whether MGMT-promoter methylation is involved in this intricate pathway as well.
To this end, I focused on creating the shMMR cell lines in the LN229 glioblastoma
cells. MMR mutations are commonly found in cancers ranging from glioblastoma to
colorectal cancer and ovarian cancer; however, treatment with TMZ has been largely
confined to glioblastoma, making the LN229 glioblastoma cells a perfect model in which
to study the role of MMR. I chose to use the short hairpin RNA (shRNA system), which is
based on creating a protein knockdown. This means that there would be reduced protein
expression, compared to the CRISPR/Cas9 system which would be used to create a total
protein knockout. Glioblastoma patients who present with MMR-mutations often show
reduced expression of the MMR protein and not complete ablation of protein expression,
making the shRNA system better than CRISPR/Cas9 for my purposes89.
The shRNA system is based upon the discovery of RNA interference (RNAi),
which is a powerful tool to study the roles of protein and gene function. shRNAs are
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artificially engineered RNA molecules consisting of a tight hairpin turn that is used to
silence gene expression and thus reduce protein expression122,123. There are two main types
of shRNAs available for use, including single stem-loop and microRNA (miR)-adapted
shRNA. The shRNA constructs used in this study to create the knockdown cell lines are
miR-adapted shRNA with the pGIPZ lentiviral vector. These shRNA constructs are
expressed as miRNA-30 primary transcripts, which allows for a Drosha processing site in
the hairpin construct to increase the efficiency of gene silencing. The specific shRNAs I
am using consist of a hairpin stem with 22 nucleotides (nt) of a double strand RNA
(dsRNA) and a 19 nt loop from miR-30. To increase both Drosha and Dicer processing,
the hairpin contains the miR-30 loop and 125 nt of miR-30 flanking sequence. Increasing
Drosha and Dicer processing allows for shRNA production and higher chance of
expressing the hairpins for gene silencing (Technical Manual GIPZ Lentiviral shRNA from
Horizon Dharmacon).
Drosha and Dicer are the required processing enzymes involved in shRNA
knockdowns. Typically, in the cytoplasm, Dicer cleaves large double stranded structures,
such as the dsRNA from our shRNA construct, into shorter fragments122,123. The dsRNA
fragments are then split into single strand fragments and bind the RNA-induced silencing
complex (RISC). These fragments guide the RISC complex to a specific gene of interest,
where the single stranded RNA binds to the mRNA of the gene of interest, resulting in its
cleavage. Similarly, in the nucleus the miR processing enzyme is known as Drosha. After
processing by Drosha, the miRNA is translocated from the nucleus to the cytoplasm, where
it is processed by Dicer and ultimately results in translational inhibition of protein
expression.
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The shRNA pGIPZ lentiviral vector acquired from Horizon Dharmacon is shown
in Figure 4.1. A key feature of this plasmid is the AmpR marker, or ampicillin resistance
marker. This marker is important during the initial steps of plasmid preparation from the
glycerol stock, to know that I can perform the miniprep and midiprep in the presence of
ampicillin and that bacteria that do not have the construct will die due to lack of the AmpR
marker. Some additional important features to point out in this vector are the turboGFP
(tGFP) tag and the puromycin resistance (PuroR) marker. The tGFP will be key in
visualizing whether the cells have taken up the plasmid under the fluorescence microscope.
Additionally, I can select the cells with puromycin and cells that do not have the construct
will die from lack of the PuroR marker. A more detailed vector map is shown in Figure
4.2.
In this chapter, I describe how I created shRNA knockdowns of human MSH2,
MSH3, MSH6, MLH1, and PMS2 in the LN229 MGMT- and MGMT+ cells. I performed
successful plasmid preparation of all the shRNA glycerol stocks, isolated plasmid DNA
with midiprep, produced lentiviral particles in HEK293T cells, and performed viral
transfection in LN229 MGMT- and MGMT+ cells. Then, I confirmed the polyclonal
populations through western blot before a single cell limiting dilution for the monoclonal
cell population and confirmed protein expression of single cell clones through western blot
once again. Ultimately, I created isogenic MMR-deficient cell lines in the MGMT- and
MGMT+ contexts which can be used as a valuable resource for studying the individual
roles of these MMR proteins in this study and many going forward.

42

Figure 4.1. pGIPZ lentiviral vector purchased from Horizon Dharmacon.

Figure 4.2. Detailed vector map of pGIPZ lentiviral vector
purchased from Horizon Dharmacon.

43

4.2.

Results
4.2.1. Plasmid preparation and restriction digest
To first create the MMR knockdowns, I acquired pGIPZ shRNA lentiviral vectors in
the form of a glycerol stock for the MMR proteins of interest except for MSH2, of
which was already available in the lab (Table 2). I thawed the glycerol stocks from
the -80C and vortexed the tubes to resuspend any E. coli that may have settled to the
bottom of the tube. I inoculated 10 µL of each individual glycerol stock into 4 mL of
Luria broth (LB) containing 100 µg/mL of ampicillin. I incubated the cultures at 37C
overnight with vigorous shaking. The next morning, I pelleted the cultures and
performed a miniprep (Qiagen QIAprep Spin Miniprep Kit, 27104) to isolate the
plasmid DNA from the bacteria. Then, I quantified the DNA isolated from each
sample with a nanodrop spectrophotometer.

For the restriction digest, I added the compounds listed in Table 4 in the order stated
to a sterile PCR tube and mixed gently to avoid bubbles. I placed the PCR tubes at
37C for 15 minutes before loading on a gel along with undigested sample for
comparison. The SacII digest should produce bands at 7927 bp, 2502 bp, and 1345 bp.
After confirming the plasmid through restriction digest, I performed a transformation
onto ampicillin plates using the successful minipreps, picked colonies to inoculate a
starter culture, and then scaled up for a midiprep to obtain a higher concentration of
DNA. I ran a SacII restriction digest on the DNA samples from midiprep and
confirmed effective plasmid preparation (Figure 4.3).
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Table 4. Restriction digest components to confirm shMMR plasmid preparation.
Component

Amount

Water, nuclease free

Up to 12.5 µL

10X CutSmart Buffer

2 µL

DNA sample in water

X µL

6X loading dye

2 µL

FastDigest Enzyme SacII

1 µL

Figure 4.3. Successful restriction digest of shMMR plasmids with SacII after
midiprep. After midiprep, the concentrations of DNA were 4.467 µg/µL of MSH3,
2.719 µg/µL of MLH1, 4.426 µg/µL of PMS2, and 1.861 µg/µL of MSH6. I loaded
2.5 µg of DNA of each sample onto the 1% agarose gel containing ethidium bromide.
In lanes that are digested, there are 3 bands indicating effective SacII digest of the
plasmid.
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4.2.2. Viral production and transfection
With the confirmed shRNA plasmid DNA for each MMR protein, I then proceeded
with viral production in the HEK293T cells expressing the oncogenic SV40 large Tantigen124. These cells have improved capacity for replication and expression of
transfected plasmids, especially those containing the SV40 origin of replication, which
all of the pGIPZ shRNA plasmids that I am using contain125.

To produce lentiviral particles in 10 cm dishes of HEK293T cells, I proceeded with a
reverse transfection, seeding cells prior to the transfection. I gathered two tubes: Tube
A containing 2 µg of VSVG envelop plasmid, 18 µg of psPAX2 packaging plasmid,
20 µg of the shRNA plasmid DNA, 10 µL of P3000 buffer from the Lipofectamine
3000 kit and 500 µL of OptiMEM media, and Tube B containing 15 µL of
Lipofectamine 3000 and 500 µL of OptiMEM media. I thoroughly mixed the
components of Tube A and Tube B at a 1:1 ratio for a total volume of 1 mL and
allowed the reaction to incubate for 15m at room temperature. Then, I added the 1 mL
to the DMEM media with HEK293T cells and allowed cells to incubate at 37C for 48
to 72 hours, harvesting the viral media at both of those time points to ensure maximum
viral production (Figure 4.4).
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Figure 4.4. Schematic for lentiviral production with the
Lipofectamine 3000 kit.

I mixed 500 µL of viral media with 500 µL of DMEM media and 8 µg/mL of
polybrene (which amounts to 0.8 µL) and transfected into 6-well dishes pre-seeded
with MGMT- and MGMT+ cells with the shRNA MMR knockdown of interest. After
48 hours, I selected cells with 1 µg/mL of puromycin for 3 to 4 days before confirming
successful viral transfection of the polyclonal population by green fluorescence under
the EVOS microscope due to the turboGFP vector found in the transfected shRNA
plasmids (Figure 4.5). I performed western blotting to confirm the polyclonal
population before proceeding with a single cell limiting dilution into 96-well plates.
Single cell clones were not cultured in puromycin selection.
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Figure 4.5. Images of polyclonal populations of LN229 cells with shRNA
knockdown of interest. Images were taken with EVOS fluorescent microscope.
Cells have taken up the shRNA plasmids of interest to varying degrees as indicated
by the intensity of the green found in each image.
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4.2.3. Screening of monoclonal shRNA knockdown cell line clones
After confirming the knockdown of the shRNA of interest in the polyclonal
populations, I performed a limiting single cell limiting dilution where I attempted to
seed 1 cell per well of a 96-well plate. The purpose of a single cell limiting dilution is
to isolate a monoclonal cell population from one cell. This one cell will form its own
colony of cells from the initial parent cell. This colony of cells is likely to be a
homogenous population with the same genetic characteristics versus a more
heterogeneous population of cells from the polyclonal population. After 1 week of
seeding single cells, I began to screen the formation of colonies for green fluorescence
under the EVOS microscope to look for clones that had successfully grown and taken
up the shRNA plasmid of interest. After moving clones from 96-well plates to 24-well
plates, to 6-well plates, I performed western blotting analysis to confirm the
knockdown of the protein of interest from multiple monoclonal cell populations. An
image of one of these western blots for the MGMT+ shMSH2 screen from various
monoclonal cell populations is shown in Figure 4.6. The long exposure in the western
blot is to be sure that the protein of interest is knocked down. Finally, I had created
isogenic cell line models with MGMT- and MGMT+ for shRNA of MSH2 *, MSH3,
MSH6, PMS2, and MLH1 cells (Figure 4.7).

*

MGMT- shMSH2 cells were created previously in the lab by Christopher Jackson.
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Figure 4.6. MGMT+ shMSH2 clone screening through western blot. This blot is a
representation of the extensive screening process required to confirm each shRNA
knockdown monoclonal cell population, taken with multiple exposures to ensure clean
knock down and decrease in protein expression.
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Figure 4.7. Western blot of shRNA mismatch repair cell line models. Each of these
blots exhibit the parental LN229 MGMT- and MGMT+ cells in the left two lanes
containing the functional MMR protein of interest. The right two lanes in all these blots
contain the MMR protein knockdown of MSH2, MSH3, MSH6 (top panel, left to right),
MLH1 and PMS2 (bottom panel, left to right).

51

It has not been described previously if mismatch repair protein knockdown would
affect the stability of its heterodimeric partner. To this end, I ran a western blot on
whole cell lysates of all the shMMR cell lines and probed for MSH2, MSH6, and MSH3
along with MLH1 and PMS2. I observed reduced levels of MSH2 protein in the
shMSH6 cells similar to the levels seen in the shMSH2 cells, and reduced levels of
MSH6 in shMSH2 cells. There was slight reduction of MSH2 in the shMSH3 cells as
well (Figure 4.8A). These data suggest that MSH2-MSH6 is unstable when one of the
heterodimeric components is knocked down, but the MSH2-MSH3 heterodimer
remains somewhat stable. Additionally, knocking down MLH1 did not seem to affect
the expression of PMS2 as much, indicating that this heterodimer may be functional
even when the expression of its partner is knocked down (Figure 4.8B).
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A

B

Figure 4.8. Western blot of stability of shMMR proteins and their
heterodimeric partner(s). (A) shMSH2 and shMSH6 cells are more
affected by each other’s knockdown than the shMSH3 cells, but not the
shMSH3 knockdown affects MSH2 and MSH6 levels. (B) shMLH1 and
shPMS2 are only slightly reduced in levels upon knockdown of their
heterodimeric partner.
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4.3.

Discussion
In this chapter, I detailed the creation of the ten isogenic LN229 shMMR cell lines

in the MGMT- and MGMT+ context. I showed the validation of the successful plasmid
preparation through a restriction digest on a 1% agarose gel, the images of the pooled cell
populations under the fluorescent microscope to show transfection efficiency, and the
western blots of the monoclonal populations of all the shMMR cells. The creation of these
cell lines will allow me to study the role of individual MMR proteins as it relates to ATR
activation upon TMZ-induced damage in the MGMT- and MGMT+ settings.
Though the western blots of the monoclonal populations show clean bands, the
process to validate the antibodies for the MMR proteins was arduous. Before creating the
shMMR cell lines, I had begun by creating transient siRNA knockdowns of the MMR
proteins for siMSH2, siMSH3, siMSH6, siMLH1, and siPMS2, to confirm the antibodies
for these proteins before proceeding with the laborious and lengthier process to create the
shMMR cells. There were numerous times where I proceeded with the western blot as
normal and the antibodies I had previously confirmed did not work. Specifically, I had
difficulty with MLH1 since I was able to confirm the MLH1 antibody in the siMLH1 cells,
but it took additional time to confirm the shMLH1 cells due to the antibody not working
as it had done prior. MSH6 also provided great difficulty, where I attempted six different
antibodies with various blocking buffer conditions and was not met with great success.
Finally, after many attempts I was able to optimize and validate all the antibodies used to
confirm the shMMR cells at the correct molecular weights. The information for these
antibodies can be found in Table 3.
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Lentiviral production in the HEK293T cells has been widely used for its ability to
create high titer virus stocks for viral transfection into the cells of interest. I did not perform
multiplicity of infection (MOI) calculations on the virus created for all the shMMR cells.
MOI is a measure of the ratio how many viral particles are present to infect the number of
host cells. For example, an MOI of 1 means that there is 1 viral particle to infect 1 cell. The
higher MOI number indicates a higher ratio of viral particles to host cells, suggesting a
higher level of transfection efficiency. There could have been repercussions by not
calculating the MOI in that the viral titer was not high enough to effectively knock down
the protein of interest. The lack of concentrating the virus could have also reduced the
efficiency of the protein knock down. In the future, it is vital to create a concentrated high
titer virus and keep track of the MOI to be confident in the potential transfection efficiency.
There are advantages and disadvantages to creating and using monoclonal
populations instead of using the polyclonal population for experiments. Using a
monoclonal population can be considered riskier due to any genetic aberrations that may
be specific to that one clone compared to a more heterogeneous polyclonal population of
cells. A good example of this is looking at the levels of MGMT in the western blots for the
shMMR MGMT+ clones as seen in Figure 4.6. Through the selection of single cells that
grow into a population of new cells, the levels of MGMT vary between clones and
compared to the LN229 MGMT+ MMR-proficient cells. This was commonly seen as I
screened dozens of clones. In many cases, I purposely chose to use the clones that contained
very high expression of MGMT, since I did not want any confusion of whether there was
MGMT expression or not. To avoid biasing the selection of monoclonal cells populations,
the polyclonal population may be used instead.
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The selection and screening of dozens of clones through western blotting can be
thought of as an inefficient process. There are other screening methods that could expedite
this process. One of these ways is through using a 96-well plate reverse transcription PCR
(RT-PCR) to measure the levels of RNA in the cells. If the shRNA knockdown was
successful, then there should be reduced levels of the mRNA from that MMR gene in the
cells. The 96-well plate format would allow the screening of many clones at once in
replicates and would allow us to see whether the RNA levels are lower in the shMMR cells
versus the controls. Another option for screening the monoclonal cells takes advantage of
the tGFP construct found in the shRNA lentiviral vector. The tGFP construct allows cells
that have taken up the shRNA to fluoresce green. These cells can be sorted through
fluorescence activated cell sorting (FACS) for GFP. This system can be employed at large
scale in 96-well plates and can screen hundreds of clones much faster than collecting cell
pellets for western blotting. There are new technologies such as the WOLF cell sorter from
nanocellect that would allow for the rapid sorting of GFP+ cells at high efficiency in either
96-well plates or even 384-well plates. Though these are some additional options for
expediting monoclonal population screening, ultimately visualizing and quantifying
protein expression with western blotting is considered the best readout to see if the shRNA
knockdown was successful.
Overall, this chapter comprehensively covered the creation of the shMMR cell
lines. In future chapters of this dissertation, these cell lines will be used heavily and
thoroughly investigated for the role of individual MMR proteins in ATR activation upon
TMZ treatment. Further, these cell lines can be used in other applications to study the role
of MMR proteins upon treatment with other drugs and in other relevant pathways.
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5. Chapter 5: Response of mismatch repair knockdown cells to
temozolomide and ATR inhibitor
5.1.

Introduction
With the newly created the shMMR cell line models in the MGMT- and MGMT+

context, I wanted to begin to test the function of individual MMR proteins upon TMZinduced damage and see how MGMT-status plays a role if any. Understanding how these
cells respond to the treatment of TMZ is imperative in learning how to treat these MMR
mutations in patients. Additionally, about 50% of cancers have a methylated MGMT
promoter so investigating the role of MGMT-status along with MMR-status can provide
us with novel information that may be useful in the clinic. Finally, MMR mutations are
common in recurrent glioblastoma where patients have been shown to be resistant to TMZ;
thus, learning about the intricacies of the MMR mutations can be beneficial to create more
targeted therapies or new biomarkers for patients with cancer87,88.
To identify how cells are responding to drug treatment, the first experiment to
perform is a short-term cell viability assay, or growth delay assay, in which one assesses
the growth of the cells upon varying concentrations of drug treatment. In this assay,
between 500 and 2000 cells are plated in each well of a 96-well plate in triplicate before
drugging with 10 concentrations of a monotherapy drug of choice, in a serial dilution from
highest to lowest concentrations. A serial dilution allows for testing of a large concentration
range of drugs. After three to six days of treatment, the cells are fixed, stained, and imaged.
Short-term cell viability assays are a good first measure of gauging working concentrations
for drugs in a variety of cell lines. Because different cell lines will respond differently to
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drug treatment, it is imperative to begin with this assay in all the shMMR cell lines before
proceeding with other assays.
After performing short-term cell viability assays to obtain a working concentration
of drugs as monotherapy, it is important to use this data for performing 2-drug synergy
assays. This assay allows for the experimentation of two different drugs for maximum cell
kill. Synergy assays are like short-term cell viability assays in that they are setup in a 96well plate format. However, each plate of a synergy assay is its own replicate, so it is
necessary to set up triplicate plates. From the 2 drugs used for synergy assays, one will
have the opportunity to test up to 10 different concentrations in a serial dilution, and the
other drug can be tested with up to 6 different concentrations. The goal of the synergy assay
for my purposes is to see whether the shMMR cells affect synergy between TMZ and ATR
inhibitor. If the knockdown of one MMR protein abrogates the synergy seen in the wildtype cells, then it suggests that the knocked down MMR protein is required for the synergy
between the two drugs. This would then allow us to probe the mechanism behind the
synergy.
Finally, the response of MMR deficiency to temozolomide and ATR inhibitor can
be assayed using a clonogenic survival assay (CSA)116. To build up to the CSA, it is
imperative that the short-term cell viability assays and synergy assays are completed to
understand the optimal concentrations to use. Because a CSA is long-term assay, the
concentrations of drug treatment are usually lower than what would be taken from the
short-term cell viability assay or synergy assay; however, understanding the concentration
range from those assays will be the deciding factor in the dosing regimen for the CSA. A
CSA is considered the gold standard of assessing the efficacy of a drug treatment or
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combination of drug treatment over the course of 10-16 days, compared to the shorter
timeline for a synergy assay. For a CSA, cells are seeded in 6-well plates in triplicate over
a range of concentrations, from 9,000 cells per well to 33 cells per well. This assay tests
the ability of cells to undergo unlimited cell division and form colonies upon drug
treatment. Because theoretically these cells can undergo unlimited cell division, the lack of
cell colonies in an effective drug treatment condition suggests that the possibility for the
tumor cells to be eradicated.
In this chapter, I employ the shMMR cell lines I created to test them for their
sensitivity to TMZ as a monotherapy, sensitivity to TMZ and ATR inhibitors in synergy
assays, and sensitivity to TMZ an ATR inhibitor in CSAs. Though these experiments may
feel redundant between all the shMMR cell lines, it is important that I thoroughly
investigate the role of individual MMR proteins for their role in TMZ-induced ATR
signaling.
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5.2.

Results
5.2.1. shMMR cells response to TMZ and ATR inhibitor as monotherapy
I sought to investigate each MMR protein individually for its sensitivity to TMZ and
ATR inhibitor. Thus, I began by performing short-term cell viability assays with the
parental LN229 MGMT- cells and the LN229 MGMT- MMR-knockdown cells. I
observed that the LN229 MGMT- cells are sensitive to TMZ as a monotherapy, as
expected (Figure 5.1). Upon increasing doses of TMZ over a 6-day treatment, the
MGMT- cells are sensitive and do not survive at high concentrations of the drug,
whereas the shMSH2, shMSH6, shMLH1, and shPMS2 cells are resistant to TMZ
treatment even at the highest concentrations. Interestingly, the shMSH3 cells are
sensitive to TMZ as a monotherapy like the MGMT- parental cell line. Further, all cell
lines regardless of MMR status are sensitive to the treatment of the ATR inhibitor
BAY-1895344 as seen from single agent dose-response curves data taken from the
Combenefit synergy plots (Figure 5.2).
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Figure 5.1. Short-term cell viability assay with temozolomide in MGMT- shMMR
cells. shMSH2, shMSH6, shMLH1, and shPMS2 MGMT- cells are resistant to the
treatment of temozolomide as a monotherapy at increasingly higher concentrations, and
shMSH3 MGMT- cells are sensitive to temozolomide treatment like the MGMT- cells.
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Figure 5.2. Short-term cell viability assay with BAY-1895344 in MGMT- shMMR cells.
There is no significant difference in sensitivity between any of these cell lines.
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5.2.2. Functional MMR is required for synergy between TMZ and ATR
inhibitors
As our previously published findings have demonstrated, TMZ sensitizes MGMTtumor cells to ATR inhibitors109; however, it is unknown whether mismatch repair
plays a role in this synergistic interaction. I tested if mismatch repair-deficient TMZresistant cells would be sensitized to the combination of TMZ and ATR inhibitor. As
seen previously, I observe exquisite synergy in LN229 MGMT- cells when treated
with TMZ and the ATR inhibitor BAY-1895344 which is not seen in LN229 MGMT+
cells (Figure 5.3A). I also observe synergy between TMZ and this ATR inhibitor in
the MSH3-deficient cells (Figure 5.3B). However, cells with the mismatch repair
deficiencies of MSH2, MSH6, MLH1, and PMS2, do not synergize with TMZ and
BAY-1895344 (Figure 5.3C-F). This data suggests that the MSH2-MSH6 and
MLH1-PMS2 heterodimers are responsible for attending to TMZ-induced mismatch
lesions, as opposed to the MSH2-MSH3 heterodimer. Cells that are mismatch repair
deficient and MGMT+ also do not exhibit synergy, indicating that MGMT-promoter
methylation status and mismatch repair status are equally important for determining
whether there are synergistic interactions between TMZ and ATR inhibitors.

I tested the synergistic combination of TMZ with another structurally unique ATR
inhibitor, AZ-20. Once again, I observe that MSH2, MSH6, MLH1, and PMS2 are
required for synergy between TMZ and this ATR inhibitor, whereas MSH3 is not
(Figure 5.4).
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MGMT-
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B

Figure 5.3. Synergy plots of shMMR cells with temozolomide and BAY1895344. (A) MMR-proficient MGMT- cells and (B) shMSH3 MGMT- cells
exhibit synergy when treated with the combination of temozolomide and
BAY-1895344.
Continued on the next page:
(C) shMSH2, (D) shMSH6, (E) shMLH1, and (F) shPMS2 cells do not
exhibit synergy when treated with the combination of temozolomide and
BAY-1895344, regardless of MGMT-status.

64

Figure 5.3 continued from the previous page.
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Figure 5.4. Synergy plots of shMMR cells with temozolomide and AZ-20. (A)
MMR-proficient MGMT- cells and (B) shMSH3 MGMT- cells exhibit synergy
when treated with the combination of temozolomide and AZ-20.

Continued on the next page:
(C) shMSH2, (D) shMSH6, (E) shMLH1, and (F) shPMS2 cells do not exhibit
synergy when treated with the combination of temozolomide and AZ-20, regardless
of MGMT-status.
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Figure 5.4 continued from the previous page.
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Further, I tested the synergistic combination of TMZ with a CHK1 inhibitor, as CHK1
is a direct downstream substrate of ATR. I observe synergy in the MGMT- cells and
MGMT- shMSH3 cells but not in other MGMT- shMMR cells, suggesting that MMR
proteins, besides MSH3, are implicated in the entire ATR/CHK1 signaling axis upon
TMZ treatment (Figure 5.5).

Figure 5.5. Synergy plots of shMMR cells with temozolomide and
CHK1 inhibitor AZD7762. Synergy is abrogated in shMMR cells
except for the (B) shMSH3 cells, indicating involvement of MMR in the
entire ATR/CHK1 signaling axis.
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I performed clonogenic survival assays using TMZ and the ATR inhibitor BAY1895344. The LN229 MGMT- cells show sensitivity to TMZ alone, and I see
increased sensitivity to the combination of TMZ and BAY-1895344. As expected
from the synergy assays, the LN229 MGMT- shMSH3 cells were sensitive to TMZ
and to the combination of TMZ and ATR inhibitor (Figure 5.6A). The LN229
MGMT- shMSH2, shMSH6, shMLH1, and shPMS2 cells are all resistant to treatment
with TMZ, and furthermore, did not respond to the combination treatment of TMZ
and ATR inhibitor (Figure 5.6B-E).

A

Figure 5.6. Clonogenic survival assay of shMMR cells with temozolomide and BAY1895344. (A) shMSH3 MGMT- cells are sensitive to temozolomide treatment alone like
the MGMT- MMR-proficient cells, and both the MGMT- and MGMT- shMSH3 cells
are even more sensitive to the combination of temozolomide and BAY-1895344.
Continued on the next page:
(B) shMSH2, (C) shMSH6, (D) shMLH1, and (E) shPMS2 are not sensitive to
temozolomide alone or the combination of temozolomide and BAY-1895344 in
clonogenic survival assay.
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Figure 5.6 continued from the previous page.
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I wanted to know whether MMR would be required for the synergistic interaction
between TMZ and other phosphatidylinositol 3- kinase (PI3K) inhibitors, or if this
synergy is confined to ATR92. Thus, I tested whether mismatch repair proteins would
be required in pathways with kinases similar to ATR, such as ATM and DNA-PK.
Unlike with ATR inhibitor, ATM inhibitor AZD0156 and DNA-PK inhibitor
AZD7648 did not display marked specificity for synergy in the LN229 MGMT- or
LN229 MGMT- shMSH2 cells with TMZ (Figure 5.7). This suggests that mismatch
repair proteins, like MSH2, are only implicated in the ATR pathway and not
necessarily the ATM or DNA-PK pathways.

Figure 5.7. Synergy plots of MGMT- and MGMT- shMSH2 cells
with temozolomide and ATM inhibitor or DNA-PK inhibitor.
Cells do not display exquisite synergy between temozolomide and
these other inhibitors as they did for ATR inhibitor.
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Further, I recapitulated the mismatch repair deficiency phenotype observed in the
LN229 MGMT- cells using another glioma cell line. I tested the combination of ATR
inhibitor and TMZ in an isogenic glioma cell line model using U251 wild-type cells
and U251 shMSH2 cells, which are both MGMT- (Figure 5.8A). As seen with the
LN229 MGMT- shMSH2 cells, the U251 shMSH2 cells are also resistant to TMZ as
a monotherapy (Figure 5.8B). Additionally, they do not exhibit synergy when treated
with TMZ and ATR inhibitors and are resistant to TMZ with the combination of ATR
inhibitor in a clonogenic survival assay (Figure 5.9). Collectively, these data suggest
that mismatch repair is required for the synergistic interaction between TMZ and ATR
inhibitors, and that mismatch repair could be involved in TMZ induced-ATR repair.

A

B

Figure 5.8. U251 shMSH2 glioblastoma cells behave similarly to LN229 MGMTshMSH2 cells. (A) Western blot of U251 cells used in this study, showing MSH2
levels and lack of MGMT compared to LN229 MGMT+ MSH2-proficient cells. (B)
Short-term cell viability assay showing that U251 shMSH2 cells are resistant to
treatment with temozolomide compared to the U251 wild-type cells.
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B

Figure 5.9. U251 shMSH2 cells are resistant to the combination of temozolomide and
ATR inhibitor. (A) Lack of synergy in U251 shMSH2 cells with temozolomide and two
different ATR inhibitors, BAY-1895344 and AZ-20 compared to U251 wild-type cells.
(B) Clonogenic survival assay shows resistance to temozolomide or the combination of
temozolomide and ATR inhibitor in the U251 shMSH2 cells compared to U251 wild-type
cells.
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5.3.

Discussion
I began testing how MMR knockdowns would affect TMZ sensitivity and ATR

inhibitor sensitivity, using the shMMR cells that I generated. In this chapter, I showed that
all MMR knockdowns except for MSH3 are sensitive to TMZ as a monotherapy in shortterm cell viability assays, though all shMMR knockdown cells are sensitive to ATR
inhibitor as a monotherapy. Furthermore, I went to show that the knockdown of MSH2,
MSH6, MLH1, and PMS2 abrogate the synergy seen between TMZ and ATR inhibitor in
the MMR-proficient cells and the shMSH3 MGMT- cells. The data also suggests a
dependence on MGMT-status as well, since the shMSH3 MGMT+ cells had an abrogation
of synergy compared to the shMSH3 MGMT- cells. The shMMR MGMT- cells besides
shMSH3 also had an abrogation of synergy upon treatment with TMZ and a CHK1
inhibitor, indicating a role for MMR proteins in the entire ATR/CHK1 signaling axis.
Clonogenic survival assays corroborated the findings of the synergy assays as well.
Overall, I showed that each MMR protein may have an individual role in ATR signaling.
The sensitivity of the shMMR cells to the ATR inhibitor alone may beg the question
of why I would test synergistic combinations with TMZ. There has been minimal data
showing the effect of ATR inhibitors in the MMR-deficient setting, so the data presented
here is novel and had not been investigated previously110. Additionally, data previously
published from our lab showed that TMZ sensitizes MGMT- cells to ATR inhibitors, yet
the role of MMR in this interaction remained unclear until further investigation109. It is
interesting that even though the shMMR cells are sensitive to ATR inhibitor alone, the
combination of TMZ and ATR inhibitor is not synergistic. This suggests that functional
MMR is required for synergistic combination, and that ATR inhibitor is not potent enough
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to overcome TMZ resistance in the MMR-deficient setting. Also, since I realized that the
shMMR cells were all equally sensitive to ATR inhibitor, I did not attempt a condition in
the CSAs with ATR inhibitor alone. I assumed the ATR inhibitor monotherapy in the CSA
would have caused cell death and lack of colony formation in all the shMMR cells, as well
as the MMR-proficient cells.
In addition to testing TMZ in combination with ATR inhibitors, I was also
interested in seeing whether MMR plays a role in other PI3K pathways. There is slight
synergy seen with both the ATM and DNA-PK inhibitors in the wild-type MMR-proficient
cells, which is abrogated in the MSH2-deficient cells. This suggests some crosstalk
between the PI3K pathways. However, the concentrations of these inhibitors used was
much higher than what is physiologically applicable, thus further investigation into a better
concentration range of these inhibitors in combination with TMZ would provide more
accurate data regarding whether MMR is involved or not. Additionally, there are many
commercially available ATM inhibitors and DNA-PK inhibitors which I could have
continued to test, to confirm that MMR does not play a role in the activation of these
kinases. I also only tested the TMZ with ATM/DNA-PK inhibitor combination in the
shMSH2 MGMT- cells, which means other MMR proteins could be implicated in these
pathways that I did not fully and thoroughly examine.
One may be considering why I did not use MMR-inhibitors in this study instead of
knocking down cell lines and treating with TMZ and ATR inhibitors, as this would still
allow me to study the role of MMR upon TMZ-induced alkylation damage and its role in
the ATR pathway. However, there is little to no information on commercially available
MMR inhibitors. The lack of MMR inhibitors is rational, as cancer patients usually present
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with MMR-deficiencies and would need to reconstitute MMR function instead of
inhibiting it. Though there have been some documented cases of MMR-overexpression,
these are rare and do not usually affect genomic stability to a great extent126.
Though I detailed my choice of the LN229 cells in Chapter 3, I performed a similar
set of assays on an isogenic pair of U251 cells. I wanted to confirm that the phenotype seen
in the LN229 shMSH2 cells were not confined specifically to that one cell line, to
generalize the findings that MMR is required for synergy between ATR inhibitors and
TMZ regardless of cell line. To be more thorough with the generalization of these findings,
I should continue these experiments in other isogenic cell lines with various MMRdeficiencies. For example, our lab has a normal human astrocyte cell line with an isogenic
pair containing an MLH1 knockout. In the future, I could use this cell line pair to test
whether the MLH1 deficiency has similar effects across multiple cell lines. Additional
studies performed in patient-derived xenograft (PDX) cell lines with an MMR-deficiency
could also help to bolster the results of this study. If the findings repeat in these cell lines,
then I can be confident that the MMR-deficient phenotype is generalizable and will perform
in a predictable manner clinically.
The synergy plots shown here were calculated from a program known as
Combenefit, which allows for the synergy output in 3 different ways: the Loewe model,
the Bliss model, and the highest single agent (HSA) model111. This means that there are
often inconsistencies when calculating and presenting synergy data because of the various
options to choose from. Because the HSA model was used in the previously published
paper from our lab, I chose to use this model to keep the results of my data consistent. The
HSA approach is also known as the cooperative effect and is defined as synergy when the
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effect of a drug combination is greater than the effect of the single drug components. This
means that if the effect of drug A is arbitrarily “2” and the effect of drug B is arbitrarily
“1”, synergy is defined as any combination that has a value greater than drug A, or “2”.
This method uses the highest number from the effect of a single agent as a threshold instead
of an additive effect which would prove to be of greater synergistic significance. In my
opinion, the Bliss model is the better model for use in calculating synergy plots. The Bliss
model states that if the effect of drug A is “2” and the effect of drug B is “1”, then synergy
is defined as any drug combination that has a value greater than “3.” This method uses a
higher threshold to calculate synergy, making the synergy seen more accurate and
dependable compared to the HSA model.
Overall, this chapter began to explore the role of individual MMR proteins upon
treatment with TMZ and ATR inhibitors through numerous, diverse assays. I found that
MSH2, MSH6, MLH1, and PMS2 are likely involved in the ATR pathway but that MSH3
is not. This segues well into the next chapter of this dissertation, which begins to
mechanistically probe the role of these MMR proteins as it relates to ATR upon TMZinduced alkylation.
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6. Chapter 6: Mechanism of DNA repair in mismatch repair
knockdown cell lines
6.1.

Introduction
After having created the MMR-deficient cell lines of interest and testing their

response to TMZ and ATR inhibitors, I was interested in understanding the underlying
mechanism of DNA repair. Often to identify the mechanisms of DNA repair, elucidating
the proteins and components involved in signaling is essential.
Cell cycle analysis through propidium iodide (PI) staining can be used to measure
the proportion of cells in each cell cycle upon various treatments and time points127. The
PI stain is stoichiometric and will bind in proportion to the amount of DNA present in the
cell. This means that cells that are in S phase will have more DNA than cells that are in G1,
and thus will absorb more dye proportionally and fluoresce more brightly than the G1 cells.
The variation in intensity of the PI allows for the quantification of cell cycle stages. PI is
the most commonly used dye in cell cycle analysis and it intercalates into the major groove
of double stranded DNA128. Typically, cells that are stained with PI produce a fluorescent
signal when excited at 488 nm and a maximum wavelength at 617 nm. Even though the
shMMR cells have the tGFP construct that can also be excited at 488 nm, the emissions of
the PI and tGFP are at different wavelengths, reassuring us that there will be little to no
interference between the PI staining and tGFP in the shMMR cells (Figure 6.1). PI staining
can provide data to see whether treatment with TMZ is causing MMR-deficient cells to be
arrested during a certain cell cycle stage. This data can then be used to investigate the DNA
repair pathways more closely.
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Immunofluorescence can be used to recognize specific proteins involved in DNA
repair, as DNA damage will cause the recruitment of many of these repair factors in the
form of foci. Each focus is meant to represent one protein at the site of damage; thus,
quantifying the number of foci over time should be an indicator of the amount of DNA
repair that is occurring129.
There are two main repair factors that I am interested in studying, γH2AX and
pRPA32 serine 33 (pRPA32 S33). γH2AX foci is a result of the histone H2 variant H2AX
being phosphorylated at residue serine 139 by either ATR, ATM, or DNA-PK130,131. These
kinases will phosphorylate H2AX to signal a double strand DNA break. γH2AX foci arrive
quickly at break sites, making this marker an effective way to study how many DNA breaks
are occurring throughout the genome132. Additionally, the γH2AX foci serves to recruit
other DNA repair factors such as proteins involved in homologous recombination or
nonhomologous end joining for the repair of the DNA damage104,130. In the field, the
phosphorylation of γH2AX is widely accepted as an early sign of DNA damage.
Quantifying γH2AX foci upon various treatment conditions and timepoints can be used as
a direct readout for the accumulation of genomic damage.
Another repair factor that I am interested in studying is pRPA32 S33. Replication
protein A (RPA) has three subunits: a 70 kilodalton (kDa) subunit, 32 kDa subunit, and 14
kDa subunit, sometimes also referred to as RPA1, RPA2, and RPA3 respectively133. The
phosphorylation of RPA32 at the serine 33 site is performed exclusively by ATR, so
studying this phosphor-site specifically can provide valuable information about ATR
activation in the shMMR cells134. This phosphorylation occurs primarily in the late S and
G2 phases of the cell cycle, most likely where there are stalled DNA replication forks.
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Moreover, pRPA32 S33 serves as a sign of replication stress, coating single-stranded DNA
at stalled or collapsed replication forks135. Mechanistically, studying pRPA32 S33 foci is
reasonable and can provide insight into whether MMR-deficiencies potentially cause
increased replication stress, increased stalled DNA replication forks, and ATR activation
upon TMZ damage.
Finally, in vivo studies can be used to uncover the underlying mechanisms of
various disease processes and to assess the potential safety and efficacy of new
treatments136. Here, I was interested in seeing whether the MMR-deficiencies affect the
treatment of mice with TMZ or ATR inhibitor (or in combination). In vivo studies are seen
as a middle ground between in vitro experiments and human trials. Thus, replicating my in
vitro data to an in vivo model system provides greater impact of the entire study, and the
findings here could potentially be translated to the clinic as a new biomarker for treatment.
In this chapter, I discuss experiments performed for cell cycle flow cytometry
studies, immunofluorescence studies, and in vivo studies. The data from these experiments
can be used to begin to piece together the mechanism of DNA repair in the shMMR cell
lines.
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Figure 6.1. Fluorescence spectra viewer showing minimal overlap between GFP
(green curve) and PI (orange curve). Image acquired from ThermoFisher.com.
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6.2.

Results
6.2.1. shMMR cells exhibit dysregulated cell cycling
I went on to probe the mechanism of distinct responses of MMR protein deficiencies
upon TMZ-mediated damage. MGMT- cells treated with TMZ undergo G2/M arrest
in the cell cycle, which is thought to be due to ATR activation and CHK1
phosphorylation. I sought to understand whether mismatch repair deficiency would
affect cell cycle progression and phase distribution. After treating cells with TMZ over
the course of 48 hours, I stained the cells with propidium-iodide for cell cycle analysis
using flow cytometry with the help of Dr. Amrita Sule. As seen previously from our
lab’s published findings, I observe an increase in G2/M arrest in the MGMT- cells after
48 hours of TMZ treatment (Figure 6.2A). The MGMT- shMSH3 cells are arrested in
G2/M after 48 hours of TMZ treatment like the MGMT- cells (Figure 6.2B). The
MGMT- shMSH2 cells do not exhibit G2/M arrest, suggesting reduced ATR activation
in these cells (Figure 6.2C). The MGMT- shMSH6 and shPMS2 and shMLH1 cells
also do not appear to be arrested in G2/M, but rather remain mostly in G1 even after
48 hours of TMZ treatment (Figure 6.2D-F). This suggests that the knockdown of
these MMR proteins (MSH2, MSH6, MLH1, and PMS2) does not activate ATR,
leading to an abrogation of G2/M arrest and a resumption of normal cell cycling.
Another way of saying this is that these MMR proteins are required for ATR activation
and G2/M arrest.
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A

B

Figure 6.2. Flow cytometry plots of shMMR cells after treatment with temozolomide.
(A) MGMT MMR-proficient cells and (B) shMSH3 MGMT- cells all exhibit elevated levels
of G2/M after 48 hours of temozolomide treatment.
Continued on the next page:
(C) shMSH2, (D) shMSH6, (E) shMLH1, and (F) shPMS2 MGMT- cells all exhibit normal
cycling compared to the untreated controls after 48 hours of temozolomide treatment.
Where indicated, ****p < 0.0001 comparing 48h G2/M of MGMT- cells with others.
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Figure 6.2 continued from the previous page.
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6.2.2. shMMR cells exhibit increased DNA replication stress
Given that I observe dysregulation of cell cycle in MMR-deficient cells, I wanted to
know if these cells had increased levels of replication stress. This can provide us with
insight into why the TMZ/ATR inhibitor synergy is abrogated in several MMRdeficient cell lines. ATR phosphorylates RPA at serine 33, which serves as a sign of
replication stress and can be observed through immunofluorescence. I also assessed
the MMR-deficient cells for increased double-stranded DNA breaks over time with
TMZ treatment, seen through γH2AX immunofluorescence. In the MGMT- cells,
there are low and steady levels of pRPA foci over time, suggesting that there is not
much replication stress upon TMZ treatment (Figure 6.3A). However, I see an
increase in γH2AX over time, suggesting increased double strand breaks, consistent
with previously published data (Figure 6.3A). MLH1 and PMS2 which comprise the
MutLα heterodimer show increased pRPA and γH2AX foci over time over 24 hours
of TMZ treatment (Figure 6.3B-C).
The MGMT- shMSH2 cells showed increases in both pRPA and γH2AX foci over
time, though there was only a slight increase (Figure 6.3D). This indicates that there
is a baseline elevated level of replication stress and double-stranded breaks in the
MSH2 knockdown cells which stays consistent over time, compared to the MGMTcells. MSH6 also shows baseline elevated levels of pRPA and γH2AX. The pRPA
levels decrease over 24 hours, indicating some resolution of replication stress (Figure
6.3E). In contrast, MSH3 which also partners with MSH2 sees increasing levels of
pRPA and γH2AX (Figure 6.3F).

85

A

B

C

Figure 6.3. Immunofluorescence of pRPA and γH2AX over time in shMMR cells
after temozolomide treatment. (A) MGMT-, (B) shMLH1, and (C) shPMS2 MGMTcells show increases in γH2AX foci over time.

Continued on the next page:
(D) shMSH2, (E) shMSH6, and (F) shMSH3 MGMT- cells have increased baseline
levels of pRPA and γH2AX foci.
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Figure 6.3 continued from the previous page.
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6.2.3. In vivo, MMR is required for synergy between TMZ and ATR inhibitors
Finally, I tested the combination of TMZ and ATR inhibitor, VX-970, with in vivo
flank tumor models using LN229 MGMT- and LN229 MGMT- shMSH6 cells with
the help of Dr. Ranjini Sundaram. After 28 days of tumor growth, Dr. Ranjini
Sundaram and I measured the tumor volumes of the mice and randomized them into
four groups with similar mean starting tumor volume. Average tumor volume per
group before beginning treatment was 81.0 mm3 ± 1.36 mm3 for LN229 MGMT-, and
89.6 mm3 ± 1.31 mm3 for LN229 MGMT- shMSH6. The treatment schedule was 4
days on/3 days off for a total of 21 days before a 14-day washout period. In those 4
treatment days, days 1 and 3 were reserved for TMZ treatment and tumor and weight
measurements. Days 2 and 4 were reserved for VX-970 and vehicle treatment
(cyclodextrin). After 21 days of treating mice (3 cycles of treatment), we continued to
measure mice for 2 weeks post-treatment. I saw that this combination treatment
regimen of TMZ and VX-970 significantly delayed tumor growth in LN229 MGMTflank tumors relative to TMZ or VX-970 alone (Figure 6.4A). In mice bearing LN229
MGMT- shMSH6 flank tumors, there was tumor growth even after the combination
of TMZ and ATR inhibitor, without reducing body weight significantly (Figure 6.4BC). Statistical significance between combination treatment and vehicle is marked with
an asterisk after performing a 2-way ANOVA, where ***P≤0.001, ****P≤0.0001.
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C

Figure 6.4. In vivo shMSH6 MGMT- tumors do not respond to treatment with
temozolomide and ATR inhibitor VX-970. (A) Mean tumor volume for mice with
MGMT- tumor, where there is a significant difference between the vehicle treated group
and the combination of temozolomide and VX-970 group. (B) Mean tumor volume for
mice with MGMT- shMSH6 tumor, with no significant difference between treatment
groups. (C) Mean weight of mice showing treatment does not cause significant toxicity
over time. ***p≤0.001, ****p≤0.0001.
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6.3.

Discussion
In this chapter, I began to elucidate the underlying mechanisms of DNA repair as

it relates to MMR-mediated ATR activation upon TMZ-induced damage. Having used a
variety of techniques including immunofluorescence, cell cycle analysis, and in vivo
studies, I am only just beginning to understand the intricacies of how MMR knockdowns
can affect DNA repair pathways.
The data from the flow cytometry cell cycle analysis suggests that MMR pathways
are involved in causing G2/M arrest upon 48 hours of TMZ treatment, as seen in the MMRproficient cell line. The shMSH2, shMSH6, shMLH1, and shPMS2 cell lines all displayed
normal cycling, meaning that the knockdown of these proteins abrogated the G2/M arrest
phenotype seen in the MMR-proficient cells. G2/M arrest is a sign of ATR activation; thus
the lack of G2/M arrest in the MMR-deficient cells suggests that these MMR proteins are
involved in the activation of ATR, as the synergy data shown previously indicated.
Additionally, flow cytometry cell cycle experiments comparing the shMMR MGMT- and
MGMT+ lines would also provide insight into how MGMT-promoter methylation affects
cell cycle progression. Finally, experiments where the MMR-deficient cells are treated with
TMZ and ATR inhibitor in combination could shed key information into whether the TMZinduced MMR-deficient cell cycling is truly related to ATR activation. It would be
beneficial to proceed with more mechanistic studies to see which proteins are specifically
involved in this signaling cascade, from ATR activation to checkpoint signaling.
The immunofluorescence data seemingly matches the flow cytometry data. In the
MGMT- cells, I see an increase in γH2AX over time, suggesting increased double stranded
DNA breaks, consistent with previously published data. This alludes to the futile cycling
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model, where overtime the TMZ-induced damage with functional MMR leads to singlestranded DNA breaks and ultimately double-stranded DNA breaks. Though I showed
destabilization of MSH6 upon MSH2-loss in Figure 4.8, the MSH6-deficient cells showed
differences in pRPA and γH2AX levels versus the MSH2-cells, indicating a unique role
for each protein in the dimer separately. Unlike the MSH2-MSH6 heterodimer, MSH2MSH3 is known for repairing larger lesions, which is a possibility for why we see an
increase in γH2AX foci over time and increased G2/M arrest in the shMSH3 cells. The
MSH6-deficient cells showed decreasing pRPA levels over time, indicating a mitigation of
replication stress which could also explain how the cells seem to be cycling normally after
48h of TMZ treatment. Given that the shMLH1 and shPMS2 cells cycle normally like the
shMSH2 and shMSH6 cells but exhibit increased pRPA and γH2AX over time, I speculate
that these proteins may use different pathway regulators for repairing damage.
In these studies, I used pRPA32 S33 for immunofluorescence studies instead of
RPA in its unphosphorylated form. RPA is upstream of ATR and will coat single-stranded
DNA to prevent it from re-annealing onto itself. RPA commonly serves as a marker for
single-stranded DNA breaks. I was more interested in looking at pRPA as it is directly
phosphorylated by ATR, which would indicate ATR activation. It also indicates replication
stress, which would allow me to delve into the DNA repair mechanisms surrounding the
role of MMR proteins in TMZ-induced ATR activation. Furthermore, I could have tested
53BP1, which is also commonly studied for double-stranded breaks in addition to γH2AX
for its recruitment of proteins involved in nonhomologous end joining137. Thus,
understanding whether there are increased single-stranded breaks with RPA and staining
for 53BP1 can provide an additional layer of mechanistic insight.
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Though the synergy assays were in ATR inhibitors other than VX-970, I used VX970 for its relevant use in current and ongoing clinical trials versus the other inhibitors. I
wanted to see the whether the mechanism of MMR-deficient resistance to TMZ and ATR
inhibitor would hold true in vivo. I chose to use MSH6-deficient cells as MSH6 is thought
to be the most mutated MMR protein in cancers, and this study would provide novel insight
into whether these tumors respond to treatment with TMZ and ATR inhibitor. Further,
there is not much of a difference between TMZ monotherapy and TMZ + ATR inhibitor
combination in the MGMT- cells. This is unlike what we have seen and published
before109. There should ideally be a larger difference between those two data points.
Additionally, patients with recurrent GBM who are TMZ-resistant after initial
chemotherapy tend to develop this resistance due to newly acquired MSH6 mutations87.
Thus, understanding whether MSH6-deficient cancer cells can be treated with the
combination of TMZ and ATR inhibitor in vivo could shed light on valuable information
for detecting new biomarker therapies for these patients.
Overall, this study begins to elucidate a novel mechanism for the individual roles
of MMR proteins in ATR activation upon TMZ treatment in MGMT-promoter methylated
cancer cells. Our data suggest that MMR proteins besides MSH3 are required for ATR
signaling, and that each distinct MMR protein serves a unique function.
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7. Chapter 7: Discussion
7.1.

Conclusions
In this study, I was first interested in recapitulating a phenotype seen in previously

published work from our laboratory to prove that MGMT-status affects ATR signaling
upon TMZ treatment. After successfully developing an IP protocol and seeing that pCHK1
levels were different in MGMT- cells vs. MGMT+ cells, I myself was able to demonstrate
that MGMT- status affects ATR activation. Then, I began to hypothesize that perhaps ATR
activation is linked to the MMR system, given that there have been numerous studies
linking the mechanism of TMZ toxicity to MMR futile cycling in MGMT- cells, and that
TMZ causes ATR activation in MGMT- cells. Thus, I was interested in understanding
whether and how the DNA MMR pathway plays a role in ATR activation upon TMZ
treatment, if any. To study my research question, I created 10 isogenic cell lines in the
MGMT- and MGMT+ settings that had shRNA knockdowns of the 5 main human MMR
proteins: MSH2, MSH3, MSH6, MLH1, and PMS2. Using these shMMR cells, I
performed short-term cell viability assays, synergy assays, clonogenic survival assays, and
even an in vivo experiment to show which MMR proteins are involved in ATR activation.
I further went on to attempt studying the intricate mechanisms of MMR in ATR activation
through cell cycle analysis with flow cytometry, and immunofluorescence.
My work here shows that MSH2, MSH6, MLH1, and PMS2 are likely implicated
in ATR activation upon TMZ treatment in MGMT- cells but MSH3 is not. This work
provides significant clinical insight into potential prognostic biomarkers for treating
patients. Many glioblastoma patients with MGMT- tumors develop resistance to TMZ, and
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though our lab’s previously published work shows that these tumors can be sensitized to
ATR inhibitors in combination with TMZ, it may not be as straight-forward as we thought.
Checking the MMR status of these tumors can help distinguish whether TMZ and ATR
inhibitor combinations would be beneficial, as it turns out that tumors with mutations in
MSH2, MSH6, MLH1, and PMS2 likely will not respond to this combination therapy.
Additionally, these cell lines that I have created have the potential to be used in future
studies to find new therapies for patients that can specifically target the MMR-deficiency.
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7.2.

Further exploration of mechanism
Though I determined which MMR proteins are required for ATR activation and

began to delve into mechanistic studies, there is a lot more work to be done here. Flow
cytometry data allowed me to visualize cell cycle effects in the shMMR cells, showing that
MLH1, PMS2, and MSH6 are responsible for ATR activation as lack of these proteins
leads to normal cycling instead of the ATR-activated G2/M arrest. Immunofluorescence
allowed me to track the presence of replication stress and double strand breaks over time,
shedding light on the dynamic kinetics of these proteins and other potential pathways and
proteins that could be involved in MMR-induced ATR activation. However, these
mechanistic studies only begin to scratch the surface and there is more work to be done
which would allow me to really understand how MMR is activating ATR. Some of these
additional studies that can be used include western blotting, comet assays, and fiber
combing assays to understand how TMZ affects MGMT- cells in the MMR-deficient
setting.
Western blotting for pCHK1 upon TMZ treatment in the shMMR cells could be
another useful metric to visualize if ATR activation is ablated without functional MMR. I
performed a western blot seen in the MGMT- cells and shMSH2 MGMT- cells with TMZ
over 24 hours and saw that there is a lack of increased ATR in the shMSH2 MGMT- cells
over time, and rather a constant level of pCHK1 that remains elevated even upon no
treatment (Figure 7.1). Further experiments such as this western blot with the other
shMMR cell lines could allow me to visualize the effects of ATR activation as it relates to
pCHK1 signaling. Additional western blots with a TMZ time course in the MGMT- vs.
MGMT- shMMR cells could probe for other proteins known to be implicated in the ATR

95

pathway such as pRPA. To be confident that the MMR-knockdowns only affect ATR
signaling, I could also perform a western blot probing for pCHK2 or pKAP1 which are
substrates of ATM; thus if there is no difference in the levels of these phosphorylated
proteins over time, one can assume that MMR is only implicated in ATR signaling and not
ATM signaling.
Comet assays are typically used to understand whether there are DNA breaks
occurring in single cells138. Because the immunofluorescence for γH2AX can show
whether there are double-stranded breaks, this assay would be more of a verification that
the foci data are reputable. Furthermore, one can use fiber combing for mechanistic studies
at the DNA level. DNA fiber combing allows DNA from cells to be stretched evenly on a
silane coated glass after 5-Iodo-2′-deoxyuridine (IdU) and 5-chloro-2′-deoxyuridine
(CldU) incorporation, which are both thymidine analogs that are incorporated into newly
synthesized DNA139. This method allows for the visualization and quantification of DNA
damage such as replication stress, replication fork progression rate, fork stability, or origin
firing. Looking at the mechanisms of MMR in ATR activation with these techniques would
provide more insight into how the DNA is being damaged upon TMZ treatment and could
offer new perspectives on treatment regiments for MMR-deficient cancer patients.
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Figure 7.1. Western blot of MGMT- and MGMT- shMSH2 cells upon
temozolomide treatment. MGMT- shMSH2 cells have an abrogation of pCHK1 signal
over time compared to the MGMT- MMR-proficient cells.
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7.3.

Other ATR inhibitors, alkylators, and combination therapies
The study here focused mainly on the use of 3 distinct ATR inhibitors: BAY-

1895344, AZ-20, and VX-970; however, there are a plethora of other ATR inhibitors
available for use. The reason I chose these inhibitors was for their commercial availability
and for their successful use in our lab previously. These inhibitors were also used in the
previously published paper from our lab that led to the conception of this project, thus I
wanted to be certain that these ATR inhibitors would work potently in the LN229 cell lines.
To reaffirm the findings from this study, I could have also used AZD6738, as is used widely
throughout the literature. AZD6738 is an analog of AZ-20, but is orally bioavailable, which
is preferable in the clinic. This ATR inhibitor is strongly selective for ATR compared to
the other PI3-like kinases such as ATM or DNA-PK, making it an excellent candidate for
use. Moreover, AZD6738 has been shown to work as a monotherapy in certain tumor
backgrounds and even in combination with carboplatin, bendamustine, cyclophosphamide,
and PARP inhibitors99. Because of its ability to synergize with bendamustine, an alkylator,
there are higher chances for synergy with temozolomide as well.
Temozolomide was used as the alkylating agent in this study since our group found
that it can sensitize MGMT- cells to the combination treatment with ATR inhibitor.
However, further studies can be completed using other alkylating agents, both
monofunctional and bifunction, to understand how the MMR pathway is involved upon
these various types of damage. For example, in addition to TMZ as a monofunctional
alkylator, dacarbazine and procarbazine, and streptozotocin could be tested too34.
Bifunctional alkylators such as cyclophosphamide and bendamustine were shown to
synergize with the ATR inhibitor AZD6738 and could be studied for the types of damage
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they cause, what pathways are activated upon that DNA damage, and whether MMR is
involved.
I mainly focused my dissertation research on the combination of TMZ and ATR
inhibitors. In the future, understanding the role of DNA damage by other alkylators and
DNA repair inhibitors in the context of MGMT-status can help solve the perplexing
mysteries of targeted therapies for MMR-deficient tumors.
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7.4. Future directions
Here, I unraveled the role of MMR proteins in ATR activation upon TMZ-induced
damage. However, this work is not completed and has only just begun. I found that certain
MMR proteins are required for ATR signaling, though the brunt of this work shows that
ATR inhibitors and TMZ are not a suitable combination in MMR-deficient cancers. The
next step is finding a therapy that can treat tumors with MMR-deficiencies.
Ongoing work from our laboratory has led to the development of a new alkylating
agent created by student Kingson Lin. This alkylating agent has shown promising data
regarding overcoming TMZ alkylator resistance in the MMR-deficient background as a
monotherapy. Preliminary data shows that this agent is safe to use in vivo as well, with
significant tumor reduction in the MMR-deficient tumors compared to TMZ alone. This is
an exciting avenue of research that may soon enter clinical trials to potentially provide a
new chemotherapy for MMR-deficient cancer patients.
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